Local synthesis of the phosphatidylinositol-3,4-bisphosphate lipid drives focal adhesion turnover

Graphical abstract

Highlights
- PtdIns(3,4)P2 produced by PI3K-C2β promote focal adhesion disassembly
- PI3K-C2β recruitment to adhesions is regulated via phosphorylation by PKN2
- Local PtdIns(3,4)P2 formation inactivates RhoA through recruitment of the ARAP3 GAP

Authors
York Posor, Charis Kampyli, Benoit Bilanges, ..., Buzz Baum, Volker Haucke, Bart Vanhaesebroeck

Correspondence
posor@fmp-berlin.de (Y.P.), bart.vanh@ucl.ac.uk (B.V.)

In brief
Remodeling of cell-matrix adhesions is crucial for development and tissue homeostasis. Posor, Kampyli et al. show that synthesis of the phosphatidylinositol-3,4-bisphosphate (PtdIns(3,4)P2) membrane lipid promotes disassembly of focal adhesions by inactivating the RhoA small GTPase. This identifies a pathway that links cessation of growth factor signaling to adhesion disassembly through a membrane lipid switch.
Local synthesis of the phosphatidylinositol-3,4-bisphosphate lipid drives focal adhesion turnover

York Posor,1,6,7,* Charis Kampyli,1,6 Benoît Bilanges,1 Sushila Ganguli,2 Philipp A. Koch,3 Alexander Wallroth,3 Daniele Morelli,1 Michelina Jenkins,1 Samira Alliouachene,1 Elitza Deltcheva,1 Buzz Baum,2,4 Volker Haucke,3,5 and Bart Vanhaesebroeck1,1

1UCL Cancer Institute, University College London, London WC1E 6DD, UK
2MRC Laboratory for Molecular Biology, University College London, London WC1E 6BS, UK
3Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Berlin 13125, Germany
4MRC Laboratory of Molecular Cell Biology, University of Cambridge, Cambridge CB2 0QH, UK
5Faculty of Biology, Chemistry, and Pharmacy, Freie Universität Berlin, Berlin 14195, Germany
6These authors contributed equally
7Lead contact
*Correspondence: posor@fmp-berlin.de (Y.P.), bart.vanh@ucl.ac.uk (B.V.)

https://doi.org/10.1016/j.devcel.2022.06.011

SUMMARY

Focal adhesions are multifunctional organelles that couple cell-matrix adhesion to cytoskeletal force transmission and signaling and to steer cell migration and collective cell behavior. Whereas proteomic changes at focal adhesions are well understood, little is known about signaling lipids in focal adhesion dynamics. Through the characterization of cells from mice with a kinase-inactivating point mutation in the class II PI3K-C2β, we find that generation of the phosphatidylinositol-3,4-bisphosphate (PtdIns(3,4)P2) membrane lipid promotes focal adhesion disassembly in response to changing environmental conditions. We show that reduced growth factor signaling sensed by protein kinase N, an mTORC2 target and effector of RhoA, synergizes with the adhesion disassembly factor DEPDC1B to induce local synthesis of PtdIns(3,4)P2 by PI3K-C2β. PtdIns(3,4)P2 then promotes turnover of RhoA-dependent stress fibers by recruiting the PtdIns(3,4)P2-dependent RhoA-GTPase-activating protein ARAP3. Our findings uncover a pathway by which cessation of growth factor signaling facilitates cell-matrix adhesion disassembly via a phosphoinositide lipid switch.

INTRODUCTION

Changing cell shape during cell-cycle progression, cell migration, and in tissue and organ development requires cells to remodel their contacts with the extracellular matrix. These contacts termed focal adhesions (FAs) are dynamic integrin-dependent organelles that link the actin cytoskeleton to the extracellular matrix and transmit contractile forces to the substratum (Pandya et al., 2017; Parsons et al., 2010). The maturation of newly formed adhesions into larger and more stable FAs depends on attachment to F-actin fibers and on actomyosin contractility (Parsons et al., 2010; Revach et al., 2020). Stress fiber formation and contractility are positively regulated by the small GTPase RhoA in its active, GTP-bound state, and its effector Rho-associated coiled-coil-containing kinase (ROCK) (Ridley, 2015). In turn, guanine nucleotide exchange factors (GEFs) recruited to FAs in response to tension can perpetuate RhoA activation (Guilluy et al., 2011; Lawson and Ridley, 2018), leading to adhesion stabilization. However, for cells to move, a dynamic turnover of adhesions and balanced regulation of RhoA is required (Lawson and Ridley, 2018; Ridley, 2015). A large number of proteins have been implicated in FA disassembly (Kuo et al., 2011; Wegner-Halle, 2012), including modulators of cytoskeletal tension and RhoA and Rac1 activities (Lawson and Burridge, 2014) and a range of other pathways (Erzatty et al., 2009; Franco et al., 2004; Kenific et al., 2016; Seetharaman and Etienne-Manneville, 2019; Sharifi et al., 2016; Stehbens et al., 2014). How the composition of the plasma membrane changes during adhesion turnover is however largely unknown.

Phosphoinositide lipids are key regulators of the actin cytoskeleton and membrane dynamics driven by filamentous F-actin (Balla, 2013; Posor et al., 2022; Tsujita and Ittoh, 2015). A key lipid in this context is phosphatidylinositol-(4,5)-bisphosphate (PtdIns(4,5)P2), produced by the PtdIns(4)P-5 kinase PIPKIIα at FAs (Di Paolo et al., 2022). PtdIns(4,5)P2 binds to and activates key adhesion components such as talin and vinculin (Di Paolo et al., 2002; Legate et al., 2011), thereby promoting adhesion formation and anchoring of actin fibers (Senju and Lappalainen, 2019). In contrast, the roles of phosphoinositides in adhesion turnover are poorly understood. Disassembly of adhesions may in part rely on PtdIns(4,5)P2 as a cofactor to recruit the clathrin protease (Franco et al., 2004; Shao et al., 2006) and to stimulate clathrin-
Figure 1. Accumulation of cell-matrix adhesions and dampened cell migration upon depletion of PI3K-C2β

(A–E) Altered morphology of cell-matrix adhesions and actin stress fibers upon depletion of PI3K-C2β. PI3K-C2β-depleted HeLa cells were (B and C) stained for paxillin or (D and E) stained for MLC2 phospho-Ser19 and for F-actin using phalloidin (laser scanning confocal microscopy). (A) Immunoblots of cell extracts (legend continued on next page)
dependent endocytosis of integrins, signaling cell-matrix adhesion receptors (Chao et al., 2010; Ezratty et al., 2009).

Phosphoinositides are known to be employed in a switch-like manner, where fate decisions of cellular structures or organelles are governed by a change in local phosphoinositide synthesis (Posor et al., 2022). This is exemplified by a switch from PtdIns(4,5)P2 to phosphatidylinositol-3,4-bisphosphate (PtdIns(3,4)P2) synthesis during clathrin-mediated endocytosis (Posor et al., 2013; Wang et al., 2019), or by cargo sorting at endosomes where a conversion of PtdIns(3)P to PtdIns(4)P promotes recycling (Ketel et al., 2016), whereas sorting along the degradative route is accompanied by consecutive formation of PtdIns(3)P and PtdIns(3,5)P2 (Schink et al., 2016). The established role for PtdIns(4,5)P2 formation in FA formation and stabilization would predict the existence of a switch to the formation of an alternate phosphoinositide lipid species during disassembly.

Possible candidates for a lipid switch triggering disassembly are phosphoinositide 3-kinases (PI3Ks), i.e., enzymes that synthesize 3-phosphoinositide lipids that dominate the endocytic and endolysosomal system. Among the PI3Ks, the class II PI3Ks have emerged as regulators of membrane dynamics at the interface of signaling and trafficking. In contrast to class I PI3K-driven PtdIns(3,4,5)P3/Akt/mTORC1 signaling, class II PI3Ks produce PtdIns(3)P and PtdIns(3,4)P2, most likely at specific subcellular locations (Bilanges et al., 2019; Gulluni et al., 2019). These include perinuclear lysosomes where PtdIns(3,4)P2 production by the class II PI3K-C2β isoform under conditions of mitogen starvation represses mTORC1 activity (Marat et al., 2017). This inhibition can be relieved by growth factor stimulation through phosphorylation of PI3K-C2β on T279 by protein kinase N2 (PKN2), which itself is activated by growth-factor-activated protein kinase on T279 by protein kinase N2 (PKN2), which itself is activated by growth-factor-activated protein kinase N2 (PKN2), which itself is activated by growth-factor-activated protein kinase

**RESULTS**

**PI3K-C2β regulates focal adhesion disassembly**

When characterizing mouse embryonic fibroblasts (MEFs) derived from our previously generated mice bearing a kinase-inactivating point mutation in PI3K-C2β (Alliouachene et al., 2015), we observed an altered cell shape. PI3K-C2β-knockdown cells did not adopt the more spread morphology, appearing larger when adhering to the culture dish. We therefore analyzed the cell-matrix disassembly of these cells by staining for the adhesion component paxillin, which revealed an accumulation of FAs in PI3K-C2β-depleted cells (Figures S1A and S1B). To expand on this finding, we turned to an easily amenable model system and assessed the morphology of cell-matrix adhesions and the actin cytoskeleton in HeLa cells. PI3K-C2β-depleted HeLa cells cultured in serum-containing media displayed a striking accumulation of FAs, with both an increase in the number of adhesions per cell and an increase in the size of the individual adhesions (Figures 1A–1C, S1E, and S1F). This was accompanied by an exacerbated formation of stress fibers and increased levels of Ser19-phosphorylated myosin light chain 2 (pMLC2Ser19), an indicator of actomyosin contractility (Figures 1D, 1E, and S1F).

We made similar observations in the migratory breast cancer cell line MDA-MB-231 (Figures S1H–S1J), suggesting a conserved role for PI3K-C2β in the regulation of cell-matrix adhesions across different cell types.

To investigate whether these morphological changes correlate with altered turnover of cell-matrix adhesions, we analyzed the dynamics of the localization of eGFP-paxillin, an established marker of FAs, in live cells. Depletion of PI3K-C2β potently reduced the rate of adhesion turnover, as illustrated by a pronounced shift in the distribution and average lifetimes of FAs (Figures 1F–1H). These observations suggest that PI3K-C2β is required for homeostatic regulation and dynamic remodeling of cell-matrix adhesions. To test the functional impact of such altered cell-matrix adhesion, we assessed the ability of cells to migrate in a scratch wound assay. PI3K-C2β depletion led to a strongly delayed wound closure, indicating impaired cell motility (Figures 1I, 1J, and S1G), in agreement with earlier observations (Domin et al., 2005; Katso et al., 2006; Maffucci et al., 2006).

We made similar observations in PI3K-C2β KD mutant MEFs (Figures S1C and S1D).

Cell-matrix adhesion dynamics are critically controlled by the rates of de novo formation of adhesions and the disassembly of existing adhesions. To understand which of these two basic components of cell-matrix adhesion turnover is affected upon PI3K-C2β depletion, we assessed these processes separately. To address de novo adhesion formation, we tetrypsinized cells and analyzed the number of adhesions per cell at different time points after re-seeding. Depletion of PI3K-C2β did not alter the number of adhesions or cell area at early time points after re-seeding (30 min or 1 h) (Figures S2A–S2C). An increased

---

**Representative of at least 5 independent experiments.** α-tubulin and GAPDH were detected as loading controls. (B and D) Scale bars, 20 μm. (E) Total fluorescence intensity per cell for phallloidin staining (F-actin) or MLC2 phospho-Ser19. (C and E) Mean + SD from n = 3 independent experiments, unpaired two-tailed t test with Welch’s correction.

(F–H) Attenuated dynamics of cell-matrix adhesions in PI3K-C2β-depleted cells. PI3K-C2β-depleted HeLa cells transiently expressing eGFP-paxillin were imaged by TIRF microscopy at 5 min/frame for 12 h.

(F) Representative kymographs along the lines drawn in the left images. Scale bars, 10 μm.

(G) Frequency of lifetimes of paxillin-labeled structures present for at least 30 min. Data shown are means + SD from n = 4 independent experiments (total of 91 cells for siScrambled, 89 cells for siPI3K-C2β).

(H) Average lifetime of paxillin-labeled adhesions analyzed as in (F). Mean + SEM from n = 4 independent experiments, unpaired two-tailed t test with Welch’s correction.

(I and J) Impaired migration in PI3K-C2β-depleted HeLa cells. Scratch wound assay with wound closure assessed after 8 and 24 h in complete medium containing serum and mitomycin C to prevent cell proliferation. (I) Bar, 200 μm. (J) Mean + SD from n = 3 independent experiments, unpaired two-tailed t test with Welch’s correction.

See also Figure S1. FA, focal adhesion.
Figure 2. PI3K-C2β is required locally for cell-matrix adhesion disassembly
(A and B) Impaired cell-matrix adhesion disassembly in PI3K-C2β-depleted HeLa cells. Adhesion disassembly was stalled by nocodazole treatment. Synchronous adhesion disassembly was then triggered by nocodazole washout for 15 min. Cells stained for paxillin and α-tubulin were imaged by spinning disk confocal microscopy. (C) Blebbistatin treatment prevents cell rounding and stress fiber formation. (D) Time course of blebbistatin-induced cell rounding in control and PI3K-C2β-KO cells. (E) Time course of eGFP-PI3K-C2β association with actin filaments in control and PI3K-C2β-KO cells. (F) Time before cell detaching in control and PI3K-C2β-KO cells. (G) Normalized fluorescence intensity of mCherry-paxillin and eGFP-PI3K-C2β in control and PI3K-C2β-KO cells.
accumulation of FAs as well as an increase in cell area were observed 6 h post re-seeding of PI3K-C2β-depleted cells compared with control cells (Figures S2A–S2C). This suggests that the de novo formation of adhesions proceeds unperturbed in the absence of PI3K-C2β, with differences only emerging over time as adhesions turn over. We therefore directly probed FA disassembly using the well-establishednocodazolet-washout protocol, which is based on the notion that an intact microtubule network is required for FA disassembly (Ezratty et al., 2005; Feutlinske et al., 2015). Microtubule depolymerization by nocodazole treatment inhibits FA disassembly, with washout of this compound triggering synchronized FA disassembly. After 15 min of nocodazole washout, PI3K-C2β-depleted cells retained more than 90% of their adhesions, while ~50% of the adhesions in control cells had undergone turnover (Figures 2A and 2B). A comparable impairment of FA disassembly was observed in MEFs (Figures S2D and S2E). These data show that the increased number and size of adhesions upon PI3K-C2β down-regulation is due to the selective impairment of FA disassembly.

We next asked whether PI3K-C2β plays a local role at cell-matrix adhesions to facilitate their disassembly. For this purpose, we turned to genome-edited HeLa cells that express eGFP-tagged endogenous PI3K-C2β (Wallroth et al., 2019). Of note, endogenous tagging of PI3K-C2β was only successful in HeLa cells of the Kyoto subclone, which display slower adhesion turnover and less migratory capacity than HeLa cells (American type culture collection #CCL-2). Whereas this limits the possible scope of experiments with these cells, it allowed us to investigate the subcellular localization of the endogenous PI3K-C2β enzyme. In these cells, PI3K-C2β displayed only sporadic co-localization with adhesions labeled with paxillin viewed by total internal reflection fluorescence (TIRF) microscopy in cells kept under steady-state culture conditions (Figure 2C, left panel). In light of our findings above, we reasoned that PI3K-C2β might selectively localize to disassembling adhesions. To capture this step of the adhesion process, we induced synchronous adhesion disassembly by treating cells with the myosin II inhibitor blebbistatin, an established procedure to relax actin stress fibers and to trigger the dismantling of mature FAs (Feutlinske et al., 2015; Parsons et al., 2010). As expected, loss of contractility upon blebbistatin addition triggered the rapid disappearance of paxillin from adhesions, correlating with a striking accumulation of eGFP-PI3K-C2β at these sites (Figures 2C and 2D; Video S1; note that the regions of interest designating adhesions were defined in the first frame and kept constant, i.e., newly forming adhesions were not considered). Recruitment of eGFP-PI3K-C2β to adhesions was also observed during spontaneous physiological adhesion turnover in cells imaged over extended periods of time (Figure 2E). Interestingly, PI3K-C2β was absent from FAs during adhesion nucleation and growth, while the onset of PI3K-C2β accumulation strikingly coincided with the decline of the paxillin signal (Figure 2E). PI3K-C2β then remained present until after paxillin had entirely disappeared from the adhesion (Figure 2E). To quantify the recruitment during physiological adhesion disassembly, we took advantage of synchronized disassembly in cells preparing to go through cell division. The continuous decline in paxillin signal at cell adhesions before detachment correlated with a steady accumulation of eGFP-PI3K-C2β, which plateaued well before cells detached (Figures 2F and 2G; Video S2), suggesting a role of PI3K-C2β in the lead-up to mitotic rounding. This is consistent with only a minor tendency to a slowed rate of cell rounding upon depletion of PI3K-C2β as measured by the rate of cell area change at the time of nuclear envelope breakdown (Figure 2H). Collectively, these data show that PI3K-C2β is specifically recruited to disassembling adhesions, in response to cell-intrinsic (i.e., before cell division) or -extrinsic cues (see below).

Recruitment of PI3K-C2β to adhesions is mediated by the adhesion disassembly factor DEPDC1B and regulated by protein kinase N downstream of mTORC2

PI3K-C2β has been implicated in the cellular response to changing environmental conditions sensed by mTORC2 (Wallroth et al., 2019), including signaling from growth factor receptors that leads to mTORC2 activation. We therefore asked whether the function of PI3K-C2β at cell-matrix adhesions is regulated in response to nutrient starvation by monitoring endogenous eGFP-PI3K-C2β in genome-engineered HeLa cells cultured in EBSS (Earle’s balanced salt solution, contains glucose but no serum or amino acids). Indeed, such starvation triggered a sustained accumulation of eGFP-PI3K-C2β at cell-matrix adhesions, reaching a plateau at about 90 min after the onset of starvation (Figures 3A and 3B).

Recent work has established that the recruitment of PI3K-C2β to membranes is inhibited by PKN2, which is activated downstream of mTORC2 signaling and RhoA activation (Wallroth et al., 2019). This inhibitory mechanism involves phosphorylation of PI3K-C2β on T279 by PKN2, which leads to inactivation of PI3K-C2β through sequestration by 14–3–3 proteins (Wallroth et al., 2019).
Figure 3. PI3K-C2β recruitment to adhesions is regulated by PKN

(A and B) Starvation induces recruitment of PI3K-C2β to cell-matrix adhesions. HeLa cells with endogenous eGFP-PI3K-C2β transiently expressing mCherry-paxillin were imaged by TIRF microscopy at 5 min/frame. After 5 frames, medium was replaced with fresh complete serum-containing culture medium or
et al., 2019). We used pharmacological inhibition of PKN2 (Wallroth et al., 2019) to test whether this protein kinase controls PI3K-C2β recruitment to cell-matrix adhesions. Pharmacological blockade of PKN2 caused the rapid and sustained recruitment of endogenous eGFP-PI3K-C2β to FAs (Figures 3C and 3D; Video S3). To address the role of PI3K-C2β phosphorylation at T279 by PKN2 by an independent approach, we compared the subcellular localization of transiently expressed eGFP-PI3K-C2β-wild-type (WT) or a PI3K-C2β-T279A mutant that cannot be phosphorylated by PKN (Wallroth et al., 2019). As shown in Figures 3E and 3F, eGFP-PI3K-C2β-T279A displayed increased enrichment at adhesions (labeled by mCherry-paxillin) in complete medium, further supporting a role of PKN2 in the recruitment of PI3K-C2β to FAs. Interestingly, PKN-inhibition-induced recruitment of PI3K-C2β to adhesions was mirrored by a sharply decreased peak of the paxillin signal (Figures 3C and 3D), suggesting that loss of PKN activity is an important regulatory signal for induction of FA disassembly. Taken together, these observations suggest a model whereby PI3K-C2β is recruited to cell-matrix adhesions to promote adhesion turnover in response to environmental conditions that dampen mTORC2 activity.

No molecular link between the adhesion-interactome and PI3K-C2β has been uncovered yet, raising the critical question of how PI3K-C2β is recruited to cell-matrix adhesions. To tackle this problem, we conducted a yeast-2-hybrid screen using the N terminus of PI3K-C2β as a bait. We identified DEPDC1B, a poorly characterized protein containing a DEP- (Dishevelled, Egl-10 and pleckstrin) domain and an inactive RhoGAP-like domain (Figure S3A). DEPDC1B associates with the transmembrane scaffold protein and tyrosine phosphatase PTPRF (protein tyrosine phosphatase receptor type F) (Marchesi et al., 2014), which localizes to FAs and organizes events related to adhesion and migration (Sarhan et al., 2016; Serra-Pagès et al., 1995). DEPDC1B has previously been implicated in facilitating FA disassembly upon cell detachment before mitosis (Marchesi et al., 2014). We first validated DEPDC1B as an interaction partner of PI3K-C2β using affinity-purification experiments. When co-expressed in HEK293T cells, 6×myc-PI3K-C2β co-immunoprecipitated with eGFP-DEPDC1B (Figure S3B). Conversely, immunoprecipitated eGFP-DEPDC1B co-purified with 6×myc-PI3K-C2β (Figure S3B). To confirm these findings under physiological conditions, we used genome-engineered HEK293T cells expressing endogenous eGFP-PI3K-C2β (Marat et al., 2017). Immunoprecipitation of eGFP-PI3K-C2β from these cells robustly co-purified endogenous DEPDC1B (Figure 4A). eGFP-PI3K-C2β immunoprecipititates also contained low levels of the adhesion scaffolding protein talin (Figure 4A). Enhancing FA recruitment of PI3K-C2β by inhibition of PKNs caused increased association of PI3K-C2β with DEPDC1B and a concomitantly reduced association with 14-3-3 proteins (Figures 4B and 4C). Taken together, these results show that PI3K-C2β and DEPDC1B form a complex in cells and that complex formation is enhanced under conditions of increased association of PI3K-C2β with FAs.

We next asked whether PI3K-C2β and DEPDC1B functionally co-operate to facilitate FA disassembly. Interestingly, depletion of DEPDC1B phenocopied loss of PI3K-C2β, with cells showing an accumulation of FAs and a more pronounced formation of actin stress fibers (Figures 4D–4F). Similar observations were made in cells in which the DEPDC1B gene had been disrupted using clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 editing (Figure S4A). Re-expression of eGFP-DEPDC1B in two separate knockout clones reduced the number of FAs and actin stress fiber formation to the levels seen in WT cells (Figures S4B and S4C). To test whether DEPDC1B promotes the localization of PI3K-C2β to cell-matrix adhesions, we induced adhesion recruitment of endogenous eGFP-PI3K-C2β in cells depleted of DEPDC1B. Pharmacological inhibition of PKN triggered the rapid accumulation of eGFP-PI3K-C2β at FAs in control cells, while a much weaker response was observed in DEPDC1B-depleted cells (Figures 4G and 4H). We conclude that DEPDC1B promotes the efficient recruitment of PI3K-C2β to cell-matrix adhesions to facilitate FA disassembly.

**PI3K-C2β-mediated synthesis of P[3,4]P₃ promotes focal adhesion disassembly**

The recruitment of PI3K-C2β to cell adhesions suggests a crucial function for local signaling lipids, i.e., 3-phosphoinositides in adhesion disassembly. To address this, we first probed whether the catalytic activity of PI3K-C2β is required in the regulation of FA disassembly. PI3K-C2β-selective kinase inhibitors are not available to date. We therefore expressed WT or KD eGFP-PI3K-C2β (Marat et al., 2017) in cells depleted of endogenous PI3K-C2β and monitored the effects on FAs. Whereas PI3K-C2β-WT restored the number of FAs as well as the size of individual adhesions and formation of stress fibers to those seen in control cells, mutant kinase-inactive PI3K-C2β was unable to rescue these phenotypes (Figures 5A and 5B). Of note, these findings are supported by our observations in MEFs from mice with KD PI3K-C2β (Alliouache et al., 2015; Figures S1A–S1D, S2D, and S2E). These findings suggest a crucial contribution of PI3K-C2β-mediated synthesis of 3-phosphoinositide lipids in FA disassembly.

Class II PI3Ks display dual lipid substrate specificity, enabling them to produce either PtdIns(3)P or PtdIns(3,4)P₂, likely depending on the substrate available in distinct subcellular compartments (Bilanges et al., 2019; Gulluni et al., 2019) and/or the presence of additional regulatory factors. The plasma membrane is known to be enriched in PtdIns(4)P (Hammond et al., 2012; starvation medium (EBSS with glucose, no serum or amino acids). (A) Scale bars, 10 μm. (B) Enrichment of eGFP-PI3K-C2β (mean intensity at adhesions over mean intensity in rest of the cell) at adhesions as labeled by paxillin in frame 1. Mean ± 95% confidence interval from n = 82 cells (complete medium) or n = 85 cells (starvation) from three independent experiments. (C and D) Inhibition of PKN triggers accumulation of PI3K-C2β at cell-matrix adhesions. HEK cells as in (A) cultured in complete medium containing serum were imaged by TIRF microscopy at 3 min/frame. After 5 frames, PKN was inhibited by addition of 1 μM PKC412 + 2 μM Cdk1/2 inhibitor III. (C) Scale bars, 10 μm. (D) Enrichment of eGFP-PI3K-C2β as in (A). Mean ± 95% confidence interval from n = 84 positions (multiple cells per position) from three independent experiments. (E and F) The T279A mutant of PI3K-C2β, which cannot be phosphorylated by PKN2, displays increased basal localization at cell-matrix adhesions. Live HEK cells transiently expressing mCherry-paxillin and either WT or T279A eGFP-PI3K-C2β were imaged by TIRF microscopy. (E) Bar, 10 μm. (F) Enrichment of eGFP-PI3K-C2β at mCherry-paxillin-labeled adhesions (as in C). Mean ± SEM from n = 4 independent experiments, unpaired two-tailed t test with Welch’s correction. See also Figure S4. FAs, focal adhesions. 1700 Developmental Cell 57, 1694–1711, July 25, 2022
Figure 4. DEPDC1B recruits PI3K-C2β to disassembling cell-matrix adhesions

(A) Endogenous PI3K-C2β and DEPDC1B form a complex in cells. Endogenous eGFP-PI3K-C2β was immunoprecipitated from HEK293 cells and strongly co-precipitated endogenous DEPDC1B, whereas talin co-purified weakly. GAPDH and Erk1/2 served as negative controls (data representing four independent experiments).

(B and C) Upon inhibition of PKN, PI3K-C2β displays enhanced complex formation with DEPDC1B, whereas interaction with 14-3-3 proteins is decreased. Cells as in (A) were treated for 2 h with vehicle or PKN inhibitors (1-μM PKC412 + 2-μM Cdk1/2 inhibitor III) and subjected to immunoprecipitation using GFP-trap resin.
Nakatsu et al., 2012) and to be 10-fold de-enriched in PtdIns compared with the total cellular PtdIns pool (Pemberton et al., 2020; Saheki et al., 2016; Zewe et al., 2020). Given that PI3K-C2β displays preference for PtdIns(4)P in vitro (Marat et al., 2017), we surmised PtdIns(3,4)P2 to be the likely product of PI3K-C2β at the plasma membrane. We tested this hypothesis by investigating whether recruitment of PI3K-C2β to FAs would cause detectable changes in PtdIns(3,4)P2 levels at these sites. To this end, we took advantage of a recently developed 3×cPH-TAPP1 biosensor for PtdIns(3,4)P2 (Goulden et al., 2019). Under basal culture conditions (i.e., in the presence of serum growth factors), a large fraction of plasma membrane PtdIns(3,4)P2 is generated by 5-phosphatase activity on PtdIns(3,4,5)P3 generated by class I PI3Ks (Goulden et al., 2019), thereby masking a potential contribution of PI3K-C2β to PtdIns(3,4)P2 synthesis.

To uncover this class II PI3K potential contribution of PI3K-C2β, we tested cells with the pan-class I PI3K inhibitor GDC-0941, which also potently inhibits PI3K-C2β-generated cytoskeletal changes, and their activity state is known to be regulated by phosphoinositides (Lawson and Ridley, 2018; Ridley, 2015). We therefore assessed the steady-state activation levels of a panel of small GTPases upon PI3K-C2β depletion. RhoA-GTP levels were found to be increased in PI3K-C2β-depleted cells, with the levels of active Rac1-GTP, Cdc42-GTP, and Arf6-GTP being likewise increased but somewhat less affected (Figures 6A–6E). No changes were observed in the GTP levels of other small GTPases, including R-Ras, which has previously been linked with adhesion turnover (Kwong et al., 2003; Zhang et al., 1996; Li et al., 2022, or of H/N/K-Ras or Arf1 (Figures 6B–6E).

The accumulation of stress fibers and increased pMLC2519 levels upon PI3K-C2β depletion (Figures 1D and 1E) are consistent with RhoA hyperactivation. We therefore analyzed whether altered RhoA activation is a cause or consequence of impaired cell-matrix adhesion turnover upon loss of PI3K-C2β-mediated PtdIns(3,4)P2-synthesis. To this end, we tested whether inhibition of ROCK, a key RhoA effector that promotes actomyosin contractility, rescues defective FA disassembly. Given that balanced RhoA activation is critical for cell-matrix adhesion dynamics, we probed the effects of partial ROCK inhibition by low doses of Y-27632, well below those known to achieve full kinase inhibition (Uehata et al., 1997; Watanabe et al., 2007). Treatment of cells with as little as 1 μM Y-27632 restored phosphorylation of the ROCK substrate MLCP2 in PI3K-C2β-depleted cells to control levels (Figures 6A and 6B). Importantly, 1 μM Y-27632 fully rescued the number and size of FAs to control levels in PI3K-C2β-depleted cells, without significant effects in control-siRNA-treated cells (Figures 6F and 6G), and completely rescued cell migration in scratch wound assays (Figures 6H and 6I). To address the role of RhoA by an independent approach, we co-depleted cells of PI3K-C2β and either RhoA or Arf6. Only depletion of RhoA fully rescued the accumulation of FAs and of F-actin in PI3K-C2β-depleted cells (Figures 6J and S6C). Taken together, these findings show that impaired adhesion turnover in PI3K-C2β-depleted cells results from RhoA hyperactivation.

Local PtdIns(3,4)P2 synthesis by PI3K-C2β downregulates RhoA via recruitment of the GAP ARAP3

We next asked how PtdIns(3,4)P2 formation might facilitate the disassembly of cell-matrix adhesions. Small GTPases of the Rho- and Ras-families are critical regulators of the formation, maturation and stability of cell-matrix adhesions and associated cytoskeletal changes, and their activity state is known to be regulated by phosphoinositides (Lawson and Ridley, 2018; Ridley, 2015). As an independent approach to investigate the lipid product of PI3K-C2β at FAs, we capitalized on the observation that the substrate specificity of PI3Ks is encoded in their activation loop (Bilanges et al., 2019; Piroia et al., 2001; Posor et al., 2013). Mutation of the 1281KRDR1281 amino acid stretch to 1281KPLP1281 in PI3K-C2β (henceforth referred to as KPLP-mutant) has been shown to abrogate the formation of PtdIns(3,4)P2 without affecting the enzyme’s ability to synthesize PtdIns(3)P (Gozzello, L. et al., Brain, 2022, personal communication). When expressed in cells depleted of endogenous PI3K-C2β, KPLP-mutant PI3K-C2β was unable to rescue the accumulation of FAs in these cells (Figures S5A and S5B), suggesting that the ability to form PtdIns(3,4)P2 is required for the role of PI3K-C2β in adhesion turnover. These combined data establish that PI3K-C2β locally synthesizes PtdIns(3,4)P2 to facilitate the disassembly of cell-matrix adhesions.

See also Figure S4. FAs, focal adhesions.
We next sought to understand the contribution of other pathways implicated in the regulation of FA disassembly to impaired adhesion turnover in PI3K-C2β-depleted cells. An important aspect of cell-matrix adhesion disassembly is the internalization of integrins via clathrin-mediated endocytosis (Ezraty et al., 2009). Indeed, PI3K-C2β has previously been reported to interact with clathrin (Wheeler and Domin, 2006) and the endocytic scaffolding protein intersectin (Das et al., 2007), yet no functional requirement in endocytosis has been described for PI3K-C2β thus far. Depletion of PI3K-C2β did not affect the endocytosis of β1-integrins as assessed by a surface biotinylation assay (Figures 6K and S7A), suggesting that defects in integrin internalization are not a direct cause underlying our observations.

PI3K-C2β has also been implicated in repressing mTORC1 activity upon cessation of growth factor signaling through the production of a local endosomally pool of PtdIns(3,4)P₂ (Marat et al., 2017; Wallroth et al., 2019). In line with this, depletion of PI3K-C2β leads to hyperactivation of mTORC1 signaling, correlated with dispersion of a late endosomal/lysosomal compartment to the cell periphery (Marat et al., 2017; Wallroth et al., 2019). Recent reports of an mTORC1-Rho-ROCK signaling pathway (Peterson et al., 2015) and of a role for peripheral late endosomal translocation in FA turnover (Schiefermeier et al., 2014) raised the question of whether our observations may pertain to regulation of mTORC1 by PI3K-C2β. If impaired cell-matrix adhesion turnover in PI3K-C2β-depleted cells was linked to increased levels of mTORC1 activity, inhibition of mTORC1 by rapamycin should rescue accumulation of cell-matrix adhesions. However, overnight treatment with rapamycin did not alter the number or size of FAs in PI3K-C2β-depleted cells (Figures S7B and S7C). These data argue against altered mTORC1 activity to underlie impaired adhesion turnover in PI3K-C2β-depleted cells.

We therefore followed the alternative hypothesis that local PtdIns(3,4)P₂ synthesis by PI3K-C2β promotes adhesion disassembly via downregulation of RhoA-GTP. Rho family GTPase-activating proteins (GAPs) frequently harbor lipid-binding domains (Amin et al., 2016), suggesting that PI3K-C2β activity may directly regulate a RhoA-inactivating GAP at disassembling FAs. Among all Rho family GAPs hitherto described, only the PH domain-containing protein ARAP3 (Krugmann et al., 2002, 2004; Stacey et al., 2004) has been found to specifically bind to PtdIns(3,4)P₂ (and, possibly, PtdIns(3,4,5)P₃) (Craig et al., 2010; Krugmann et al., 2002) in vitro and to endosomes enriched in PtdIns(3,4)P₂ in living cells (Lee et al., 2019). Moreover, the reported substrate specificity of ARAP3 matches precisely with the observed changes in GTP levels of RhoA, Rac1, Cdc42, and Arf6 in PI3K-C2β-depleted cells (Krugmann et al., 2002; Song et al., 1998). We therefore hypothesized that ARAP3 acts as a PtdIns(3,4)P₂ effector of PI3K-C2β to direct cell-matrix adhesion disassembly. Indeed, ARAP3 depletion led to an accumulation of FAs and of F-actin stress fibers (Figures 7A and 7B), akin to PI3K-C2β loss.

If ARAP3 was an effector of PI3K-C2β activity, it would be predicted that regulation of adhesion turnover requires the ability of ARAP3 to bind phosphoinositides (i.e., PtdIns(3,4)P₂ and PtdIns(3,4,5)P₃) (Craig et al., 2004) or lipid-binding-deficient (R307A,R308A) eGFP-ARAP3 mutants (Krugmann et al., 2002). Whereas WT ARAP3 restored FA numbers and stress fiber formation to control levels, re-expression of GAP-deficient or lipid-binding-deficient ARAP3 mutants failed to rescue these phenotypes (Figures 7A and 7B). Moreover, overexpression of WT but not GAP-deficient ARAP3 in PI3K-C2β-depleted cells was sufficient to reduce the number of FAs (Figure 7C). These data suggest that PI3K-C2β may recruit ARAP3 to disassembling adhesion sites. To probe this hypothesis further, we monitored the local nanoscale recruitment of both proteins in live cells. To this aim, cells were treated with blebbistatin to induce FA disassembly, eGFP-PI3K-C2β and mCherry-ARAP3 were enriched at disassembling adhesions and displayed overlapping time courses of recruitment (Figures 7D–7F). Importantly, recruitment of ARAP3 to FAs was attenuated in PI3K-C2β-depleted cells (Figures 7G and 7H).

These collective data establish ARAP3 as a PtdIns(3,4)P₂ effector of PI3K-C2β in cell-matrix adhesion disassembly.

DISCUSSION

Despite a detailed understanding of the proteomic changes associated with cell-matrix adhesion turnover (Revach et al., 2020), it has remained unclear how the composition of the membrane affects these dynamics. Here, we unravel a pathway that links signaling input into the PKN2 Ser/Thr kinase (Wallroth et al., 2019) to the local formation of PtdIns(3,4)P₂ to trigger disassembly of FAs. Our findings suggest a model whereby the lack of stimulation of PI3K-C2β at FAs through association with DEPDC1B, a poorly characterized protein implicated in adhesion disassembly (Marchesi et al., 2014), This results in the formation of PtdIns(3,4)P₂ by PI3K-C2β at

Figure 5. PI3K-C2β-mediated synthesis of PtdIns(3,4)P₂ triggers focal adhesion disassembly

(A and B) Focal adhesion morphology in PI3K-C2β-depleted cells is reconstituted by re-expression of WT but not kinase-dead PI3K-C2β. SilRNA-treated cells were transfected with eGFP or either siRNA-resistant WT or kinase-dead eGFP-PI3K-C2β and stained for paxillin and F-actin (laser scanning confocal microscopy). (A) Scale bars, 20 μm. (B) Mean ± SD from n = 5 independent experiments, two-way ANOVA with Tukey’s test. (C–F) The P(3,4)P₂ sensor 3 × cPH-TAPP1 displays recruitment to cell-matrix adhesions in a PI3K-C2β-dependent manner. HeLa cells with endogenous eGFP-PI3K-C2β transiently expressing mCherry-3 × cPH-TAPP1 and mCherry-ARAP3 were imaged by TIRF microscopy at 3 min/frame. After 30 min, cells were treated with (C and D) 250 nM GDC-0941 (a pan-class I PI3K inhibitor sparing PI3K-C2β) or (E and F) 1 μM PI-103 (a pan-class I PI3K inhibitor hitting PI3K-C2β at IC₅₀ = 26 nM). After 90 min, cells were additionally subjected to PKN inhibition (1 μM PKC412 + 2 μM Cdk1/2 inhibitor II) to trigger recruitment of PI3K-C2β to adhesions. (C and E) Scale bars, 10 μm. (D and F) Recruitment of mCherry-3 × cPH-TAPP1 and eGFP-PI3K-C2β at focal adhesions was quantified as mean intensity at adhesions (as labeled by IRFP-paxillin in first frame) over mean intensity in the rest of the cell. Mean ± 95% confidence interval from n = 54 cells (GDC-0941 + vehicle), n = 62 cells (GDC-0941 + PKNii), n = 63 cells (PI-103 + PKNii) from three independent experiments and n = 44 cells (PI-103 + vehicle) from two independent experiments.

KD, kinase-dead; FAs, focal adhesions.
Figure 6. Increased RhoA-GTP levels underlie impaired adhesion turnover

(A–E) Increased basal GTP levels of Rho- and Arf-family GTPases in cells depleted of PI3K-C2β as assayed by pull-downs using GST (control), GST-PAK-PBD, GST-Rhotekin-RBD, GST-Raf-RBD, or GST-GGA3VHS-GAT. GTPγS-loaded lysates served as a positive control. Rhot., Rhotekin.

(F) ROCK inhibitor Y-27632

(G) siScrambled siPI3K-C2β

(H) 0 h 16 h

(D) siScrambled siPI3K-C2β

(E) siScrambled siPI3K-C2β

(J) siPI3K-C2β

(K) siPI3K-C2β

(legend continued on next page)
FAs, promoting recruitment of the Rho-GAP ARAP3 and downregulated RhoA activity, tipping the balance toward adhesion disassembly. Our results further imply that whereas formation and stabilization of FAs are driven by Ptdlns(4,5)P₂ synthesis (Di Paolo et al., 2002; Legate et al., 2011), a switch to Ptdlns(3,4)P₂ generation then facilitates adhesion disassembly via inactivation of RhoA. The local conversion of phosphoinositide lipids (also called “lipid switch”) is an emerging theme in endo-exocytic membrane traffic (Wang et al., 2019) as well as the regulation of lysosomal membrane dynamics (Ebner et al., 2019). In this context, PI3K-C2β appears to function as a mediator of the cellular response to starvation by producing local pools of Ptdlns(3,4)P₂ to confer repression of mTORC1 on lysosomes (as reported by us earlier (Marat et al., 2017; Wallroth et al., 2019)) and to concomitantly initiate turnover of cell-matrix adhesions at the plasma membrane (this study). Interestingly, FAs may serve as mTORC1 activation hubs (Rabanal-Ruiz et al., 2021), further integrating the function of PI3K-C2β in FA disassembly identified here with its role in the cellular response to starvation.

The Ptdlns(4)P used by PI3K-C2β at FAs could derive from the plasma membrane Ptdlns(4)P-pool, which is known to largely depend on PI4KIIIα (Nakatsu et al., 2012) and/or could require local formation from Ptdlns(4,5)P₂ by a 5’-phosphatase such as SHIP2, which indeed has been implicated in FA disassembly (Fukumoto et al., 2017). Counter-transport of Ptdlns(4)P and phosphatidylcholine from the endoplasmic reticulum by the lipid transfer protein ORP3 has recently been reported to facilitate FA disassembly (D’Souza et al., 2020), suggesting that Ptdlns(4)P may thus contribute to adhesion disassembly by serving as a substrate for both PI3K-C2β and ORP3.

Release from inhibitory 14-3-3 proteins enables PI3K-C2β to associate with different cellular organelles, mediated by Rab7/Raptor on endolysosomes (Marat et al., 2017; Wallroth et al., 2019) and DEPDC1B at FAs (Figure 4). Unlike reported for DEPDC1B (Marchesi et al., 2014), we found no significantly delayed mitotic entry in PI3K-C2β-depleted HeLa cells (Figures 2H and 2I), and indeed observed pronounced accumulation of PI3K-C2β at FAs in cells preparing for cytokinesis well before detachment (Figures 2F and 2G). This may reflect known differences in the disassembly of cell-matrix adhesions in interphase and mitosis (Dix et al., 2018; Ramkumar and Baum, 2016), with a more prominent role of PI3K-C2β in the turnover of adhesions during interphase.

Not only cell-matrix but also cell-cell adhesions are closely connected with the actomyosin cytoskeleton, with balanced RhoA activation being similarly important for maintenance and stabilization of adherens junctions as it is for cell-matrix adhesions (Citi et al., 2014; Sahai and Marshall, 2002; Terry et al., 2011). Interestingly, a recent study reports that inhibition of PI3K-C2β strengthens the vascular barrier by stabilizing VE-cadherin at adherens junctions (Anquetil et al., 2021). ARAP3 is also expressed in endothelia (Van Buul et al., 2014) and essential for developmental angiogenesis (Gambardella et al., 2010), raising the possibility of a more widespread relevance of our findings in the regulation of cellular adhesion. Future research will have to clarify the roles of PI3K-C2β in regulating both cell-matrix and cell-cell adhesion in epithelia, which are of high relevance not only for cardiovascular disorders (Anquetil et al., 2021) but also cancer metastasis and organ development (Pandya et al., 2017).

**Limitations of the study**

An interesting observation is that enrichment of PI3K-C2β persists at sites of disassembled adhesions, well after adhesion markers such as paxillin have dissociated from the adhesive structures (Figures 2E–2G). This could reflect a requirement for sustained local RhoA inactivation to ensure continued adhesion dismantling despite the presence of activated integrins, preventing re-growth of the adhesion. A non-exclusive alternative explanation, which we have not explored in depth in this study, is that PI3K-C2β might facilitate the internalization of integrins (Ernott et al., 2009), an endocytic cargo that is known to cause increased resistance to internalization (Bascieri et al., 2018). As we did not observe changes in the internalization of total β1-integrins (Figures 6K and S7A), a severe effect of PI3K-C2β depletion on the endocytic process itself appears unlikely. However, we cannot exclude a specific role of PI3K-C2β in the endocytosis of active β1-integrins.

The implications of our findings for tissue development and maintenance (Pandya et al., 2017; van der Stoel et al., 2020) remain to be explored. FAs in migrating epithelial sheets are distributed asymmetrically, with leader cells at the migratory front forming stronger matrix adhesions and generating contractile forces to pull the follower cells (De Pascalis and Ettienne-Manneville, 2017). Our observations suggest that during migration along a growth factor gradient, lower PKN2 activity in follower cells might promote PI3K-C2β-dependent FA turnover. This would weaken cell-matrix adhesion to permit passive cell movement, whereas high growth factor input at the migratory front would keep PI3K-C2β inactive, thereby ensuring stable matrix adhesion to generate the necessary contractile force.

### Quantification of immunoblot data

- **Fas, paxillin.** Quantification of immunoblot bands as shown in (A), (B), and (D). Mean ± SEM from n = 6 (RhoA), n = 3 (Rac1, R-Ras, and Arf6) independent experiments, one sample, two-tailed t test with hypothetical mean of 1.0. (F and G) Titration of the ROCK inhibitor Y-27632 on HeLa cells depleted of PI3K-C2β. Cells were treated with the indicated concentration of Y-27632 for 16 h overnight and stained for paxillin and imaged with a spinning disk confocal microscope. (F) Scale bars, 20 μm. (G) 1 μM Y-27632 rescues focal adhesion morphology defects in PI3K-C2β-depleted cells. Mean ± SD from n = 3 independent experiments, two-way ANOVA with Tukey’s test. (H and I) Rescue of migration by low-dose Y-27632 ROCK inhibitor (1 μM) in PI3K-C2β-depleted cells in the scratch wound assay after 8 and 16 h (in serum- and mitomycin-C-containing media). (H) Scale bars, 100 μm. (I) Mean ± SD from n = 3 independent experiments, two-way ANOVA with Sidak’s test. (J) Co-depletion of RhoA, but not of Arf6, rescues focal adhesion morphology defects in PI3K-C2β-depleted cells. HeLa cells were siRNA treated as indicated (see also Figure S6C) and stained for paxillin (spinning disk confocal microscopy). Mean ± SD from n = 4–8 independent experiments, one-way ANOVA with Dunnett’s test.

### The endocytosis of total β1-integrins

- **β1-integrins are not affected by depletion of PI3K-C2β.** The amount of β1-integrin internalized after different time points was measured using a surface biotinylation and streptavidin pull-down assay (see STAR Methods). Mean ± SEM from n = 4 independent experiments, multiple unpaired t test with Welch’s correction. See also Figure S6. FAs, focal adhesions.

1706 Developmental Cell 57, 1694–1711, July 25, 2022
Figure 7. PI3K-C2β promotes the recruitment of the RhoA-GAP ARAP3 to disassembling adhesions

(A) Immunoblot analysis of HeLa cells treated with siRNAs against PI3K-C2β or ARAP3. α-tubulin and GAPDH were detected as loading controls. Data shown are representative of five independent experiments.
STAR METHODS

Detailed methods are provided in the online version of this paper and include the following:

- **KEY RESOURCES TABLE**
- **RESOURCE AVAILABILITY**
  - Lead contact
  - Materials availability
  - Data and code availability
- **EXPERIMENTAL MODEL AND SUBJECT DETAILS**
- **METHOD DETAILS**
  - Plasmids
  - Antibodies
  - siRNAs
  - Inhibitors and chemicals
  - DNA and siRNA transfection
  - Immunocytochemistry and confocal microscopy
  - TIRF imaging
  - Cell extracts and immunoblotting
  - Immunoprecipitations
  - GTPase pull-down assays
  - Scratch wound migration assay
  - Nocodazole washout assay
  - Yeast-2-hybrid screen
  - RNA isolation and RT-qPCR
  - Genome-editing using CRISPR/Cas9
  - Generation of mouse embryonic fibroblasts
  - Surface biotinylation
  - 1-integrin endocytosis
  - Measurement of mitotic rounding
- **QUANTIFICATION AND STATISTICAL ANALYSIS**
  - Image analysis
  - Statistics

SUPPLEMENTAL INFORMATION

Supplemental information can be found online at https://doi.org/10.1016/j.devcel.2022.06.011.

ACKNOWLEDGMENTS

We thank Maria Whitehead, Romain Galmes, and Lennart Hoffmann for help during early stages of the project; Jiten Manji for help with microscopy; Elena Lopez-Guadamillas, Evelyn Lau, and Raittsa Madsen for help with qRT-PCR and CRISPR-Cas9 gene editing; and Helen Mathews for help with data interpretation on mitotic rounding. Personal fellowships were from EMBO (ALTF Lopez-Guadamillas, Evelyn Lau, and Ralitsa Madsen for help with qRT-PCR during early stages of the project; Jiten Manji for help with microscopy; Elena We thank Maria Whitehead, Romain Galmes, and Lennart Hoffmann for help with qRT-PCR during early stages of the project; Jiten Manji for help with microscopy; Elena}

REFERENCES

Allouache, S., Bilanges, B., Chicanne, G., Anderson, K.E., Pearce, W., Ali, K., Valet, C., Posor, Y., Low, P.C., Chaussade, C., et al. (2015). Inactivation of the Class II PI3K-C2β potentiates insulin signaling and sensitivity. Cell Rep 13, 1881–1894. https://doi.org/10.1016/j.celrep.2015.10.052.

Amin, E., Jaiswal, M., Derewenda, U., Reis, K., Koessmeier, K.T., Aspenström, P., Somlyo, A.V., Dvorsky, R., and Ahmadian, M.R. (2016). Deciphering the molecular and functional basis of RHOGAP family proteins: A systematic approach toward selective inactivation of RHO family proteins. J. Biol. Chem. 291, 20353–20371. https://doi.org/10.1074/jbc.M116.736967.

Anquetil, T., Soliniac, R., Jaffre, A., Vlaud, J., Darcourt, J., Orset, C., Geuss, E., Kleinschnitz, C., Vanhaesebroeck, B., Vivien, D., et al. (2021). PI3Kα2β inactivation stabilizes VE-cadherin junctions and preserves vascular integrity. EMBO Rep 22, e10299. https://doi.org/10.15252/embr.2020051299.
Morpholin-4-yl thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J. Med. Chem. 51, 5522–5532. https://doi.org/10.1021/jm800295d.

Franco, S.J., Rodgers, M.A., Perrin, B.J., Han, J., Bennin, D.A., Critchley, D.R., and Huttenlocher, A. (2004). Calpain-mediated proteolysis of talin regulates adhesion dynamics. Nat. Cell Biol. 6, 977–983. https://doi.org/10.1038/ncb1175.

Fukumoto, M., Ijuin, T., and Takenawa, T. (2017). PI(3,4,5)P3 plays critical roles in the regulation of focal adhesion dynamics of MDA-MB-231 breast cancer cells. Cancer Sci. 108, 941–951. https://doi.org/10.1111/cas.13215.

Gambardella, L., Hemberger, M., Hughes, B., Zudaire, E., Andrews, S., and Vermeren, S. (2010). PI(3)K signaling through the dual GTPase-activating protein ARAP3 is essential for developmental angiogenesis. Sci. Signal. 3, ra76. https://doi.org/10.1126/scisignal.2001026.

Goulden, B.D., Pacheco, J., Dull, A., Zewe, J.P., Deiters, A., and Hammond, G.R.V. (2019). A high-avidity biosensor reveals plasma membrane PI(3,4,5)P3 is predominantly a class I PI3K signaling product. J. Cell Biol. 218, 1066–1079. https://doi.org/10.1083/jcb.201809026.

Guilluy, C., Swaminathan, V., Garcia-Mata, R., O’Brien, E.T., Superfine, R., and Burridge, K. (2011). The Rh0 GEFs LARG and GEF-H1 regulate the mechanical response to force on integrins. Nat. Cell Biol. 13, 722–727. https://doi.org/10.1038/ncll2254.

Gullini, F., De Santis, M.C., Margaria, J.P., Martini, M., and Hirsch, E. (2019). Class II PI3K functions in cell biology and disease. Trends Cell Biol 29, 339–359. https://doi.org/10.1016/j.tcb.2019.01.001.

Hammond, G.R.V., Fischer, M.J., Anderson, K.E., Holdich, J., Koteci, A., Balla, T., and Irvine, R.F. (2012). PI4P and PI(4,5)P2 are essential but independent lipid determinants of membrane identity. Science 337, 727–730. https://doi.org/10.1126/science.1222483.

Stacey, T.T., Nie, Z., Stewart, A., Najdovska, M., Hall, N.E., He, H., Randazzo, P.A., and Lock, P. (2004). ARAP3 is transiently tyrosine phosphorylated in cells attaching to fibronectin and inhibits cell spreading in a Rh0GAP-dependent manner. J. Cell Sci. 117, 6071–6084. https://doi.org/10.1242/jcs.01526.

Katsos, R.M., Pardo, O.E., Palamidessi, A., Franz, C.M., Marinov, M., De Laurentis, A.D., Downward, J., Scita, G., Ridley, A.J., Waterfield, M.D., et al. (2006). Phosphoinositide 3-kinase C2β regulates cytoskeletal organization and cell migration via Rac-dependent mechanisms. Mol. Biol. Cell 17, 3729–3744. https://doi.org/10.1091/mbc.e05-11-1083.

Kenific, C.M., Stehbens, S.J., Goldsmith, J., Leidal, A.M., Faure, N., Ye, J., Wittmann, T., and Debnath, J. (2016). NBR 1 enables autophagy-dependent focal adhesion turnover. J. Cell Biol. 212, 577–590. https://doi.org/10.1083/jcb.201503075.

Ketel, K., Krauss, M., Nicot, A.-S., Puchkov, D., Wieser, M., Muller, R., Subramanian, D., Schultz, C., Laporte, J., and Haucke, V. (2016). A phosphoinositide conversion mechanism for exit from endosomes. Nature 529, 408–412. https://doi.org/10.1038/nature16516.

Knight, Z.A., Gonzalez, B., Feldman, M.E., Zunder, E.R., Goldenberg, D.D., Williams, O., Loewer, R., Stokoe, D., Balla, A., Toth, B., et al. (2006). A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell 125, 733–747. https://doi.org/10.1016/j.cell.2006.03.035.

Krugmann, S., Anderson, K.E., Ridley, S.H., Risso, N., McGregor, A., Coadwell, J., Davidson, K., Eguinoa, A., Eillson, C.D., Lipp, P., et al. (2002). Identification of ARAPs, a novel PI3K effector regulating both Arf and Rh0 GTPases, by selective capture on phosphoinositide affinity matrices. Mol. Cell 9, 95–106. https://doi.org/10.1016/S1089-2760(02)00434-3.

Krugmann, S., Williams, R., Stephens, L., and Hawkins, P.T. (2004). ARAP3 is a PI3K- and rap-regulated GAP for Rh0a. Curr. Biol. 14, 1380–1384. https://doi.org/10.1016/j.cub.2004.07.058.

Kuo, J.C., Han, X., Hsiao, C.T., Yates, J.R., and Waterman, C.M. (2011). Analysis of the myosin-ll-responsive focal adhesion proteome reveals a role for β-Pix in negative regulation of focal adhesion maturation. Nat. Cell Biol. 13, 383–393. https://doi.org/10.1038/ncb2216.

Kwong, L., Wozniak, M.A., Collins, A.S., Wilson, S.D., and Keely, P.J. (2003). R-Ras promotes focal adhesion formation through focal adhesion kinase...
Stehbens, S.J., Paszek, M., Pemble, H., Ettinger, A., Gierke, S., and Wittmann, T. (2014). CLASPs link focal-adhesion-associated microtubule capture to localized exocytosis and adhesion site turnover. Nat. Cell Biol. 16, 561–573. https://doi.org/10.1038/ncb2975.

Terry, S.J., Zihni, C., Elbediwy, A., Vitiello, E., Leefa Chong San, I.V., Balda, M.S., and Matter, K. (2011). Spatially restricted activation of RhoA signalling at epithelial junctions by p114RhoGEF drives junction formation and morphogenesis. Nat. Cell Biol. 13, 159–166. https://doi.org/10.1038/ncb2156.

Tinevez, J.Y., Perry, N., Schindelin, J., Hoopes, G.M., Reynolds, G.D., Laplantine, E., Bednarek, S.Y., Shorte, S.L., and Eliceiri, K.W. (2017). TrackMate: an open and extensible platform for single-particle tracking. Methods 115, 80–90. https://doi.org/10.1016/j.ymeth.2016.09.016.

Tsujita, K., and Itoh, T. (2015). Phosphoinositides in the regulation of actin cortex and cell migration. Biochim. Biophys. Acta 1851, 824–831. https://doi.org/10.1016/j.bbalip.2014.10.011.

Uehata, M., Ishizaki, T., Satoh, H., Uno, T., Kawahara, T., Morishita, T., Tamakawa, H., Yamagami, K., Inui, J., Maekawa, M., and Narumiya, S. (1997). Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 389, 990–994. https://doi.org/10.1038/389990a0.

Van Buul, J.D., Geerts, D., and Huveneers, S. (2014). Rho GAPs and GEFs: controlling switches in endothelial cell adhesion. Cell Adh. Migr. 8, 108–124. https://doi.org/10.4161/cam.27599.

van der Stoel, M., Schimmel, L., Nawaz, K., van Staalborch, A.M., de Haan, A., Klaus-Bergmann, A., Valent, E.T., Koenis, D.S., van Nieuw Amerongen, G.P., de Vries, C.J., et al. (2020). DLC1 is a direct target of activated YAP/TAZ that drives collective migration and sprouting angiogenesis. J. Cell Sci. 133. https://doi.org/10.1242/jcs.239947.

Wallerth, A., Koch, P.A., Marat, A.L., Krause, E., and Haucke, V. (2019). Protein kinase N controls a lysosomal lipid switch to facilitate nutrient signalling via mTORC1. Nat. Cell Biol. 21, 1093–1101. https://doi.org/10.1038/s41556-019-0377-3.

Wang, H., Lo, W.T., and Haucke, V. (2019). Phosphoinositide switches in endocytosis and in the endolysosomal system. Curr. Opin. Cell Biol. 59, 50–57. https://doi.org/10.1016/j.celrep.2019.03.011.

Watanabe, K., Ueno, M., Kamiya, D., Nishiyama, A., Matsumura, M., Wataya, T., Takahashi, J.B., Nishikawa, S., Nishikawa, S., Muguruma, K., and Sasai, Y. (2007). A ROCK inhibitor permits survival of dissociated human embryonic stem cells. Nat. Biotechnol. 25, 681–686. https://doi.org/10.1038/nbt1310.

Wehrle-Haller, B. (2012). Assembly and disassembly of cell matrix adhesions. Curr. Opin. Cell Biol. 24, 569–581. https://doi.org/10.1016/j.jceb.2012.06.010.

Wheeler, M., and Domin, J. (2006). The N-terminus of phosphoinositide 3-kinase-C2beta regulates lipid kinase activity and binding to clathrin. J. Cell. Physiol. 206, 586–593. https://doi.org/10.1002/jcp.20507.

Zewe, J.P., Miller, A.M., Sangappa, S., Wills, R.C., Goulven, B.D., and Hammond, G.R., V. (2020). Probing the subcellular distribution of phosphatidylinositol reveals a surprising lack at the plasma membrane. J. Cell Biol. 219, e201906127. https://doi.org/10.1083/jcb.201906127.

Zhang, Z., Vuori, K., Wang, H.G., Reed, J.C., and Ruoslahti, E. (1996). Integrin activation by R-ras. Cell 85, 61–69. https://doi.org/10.1016/S0092-8674(00)81082-X.
## STAR METHODS

### KEY RESOURCES TABLE

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| **Antibodies**      |        |            |
| Mouse monoclonal anti-paxillin | BD Bioscience | Cat# 610051; RRID: AB_397463 |
| Mouse monoclonal anti-phospho-MLC2 S19 | Cell Signaling Technology | Cat# 3675; RRID: AB_2250969 |
| Rabbit polyclonal anti-total MLC2 | Cell Signaling Technology | Cat# 3672; RRID: AB_10692513 |
| Mouse monoclonal anti-α-tubulin | Merck (Sigma-Aldrich) | Cat# T5168; RRID: AB_477579 |
| Mouse monoclonal anti-c-myc | Abcam | Cat# ab32; RRID: AB_303599 |
| Mouse monoclonal anti-FLAG | Merck (Sigma-Aldrich) | Cat# F-3165; RRID: AB_259529 |
| Rabbit polyclonal anti-mouse IgG | Merck (Sigma-Aldrich) | Cat# M-7023; RRID: AB_260634 |
| Rabbit polyclonal anti-DEPDC1B | Biorty | Cat# orb183064 |
| Rabbit polyclonal anti-DEPDC1B | MyBiosource | Cat# mbs154376 |
| Mouse monoclonal anti-DEPDC1B | Merck (Sigma-Aldrich) | Cat# SAB1403301; RRID: AB_10738419 |
| Mouse monoclonal anti-β-actin | Merck (Sigma-Aldrich) | Cat# A1978; RRID: AB_476692 |
| Mouse monoclonal anti-PI3K-C2β | BD Bioscience | Cat# 611342; RRID: AB_398864 |
| Mouse monoclonal anti-Talin | Merck (Sigma-Aldrich) | Cat# T3287; RRID: AB_477572 |
| Rabbit polyclonal anti-eGFP | Abcam | Cat# ab6556; RRID: AB_305564 |
| Rabbit polyclonal anti-Erk1/2 | Cell Signaling Technology | Cat# 9102; RRID: AB_330744 |
| Mouse monoclonal anti-14-3-3 (pan) | Santa Cruz Biotechnology | Cat# sc-1657; RRID: AB_626618 |
| Rabbit polyclonal anti-RhoA | Cell Signaling Technology | Cat# 2117; RRID: AB_10693922 |
| Mouse monoclonal anti-RAC1 | Merck-Millipore | Cat# 05-389; RRID: AB_309712 |
| Rabbit polyclonal anti-Cdc42 | Cell Signaling Technology | Cat# 2462; RRID: AB_2078085 |
| Mouse monoclonal anti-vinculin | Merck (Sigma-Aldrich) | Cat# V9131; RRID: AB_477629 |
| Rabbit polyclonal anti-R-Ras | Cell Signaling Technology | Cat# 8446; RRID: AB_10838402 |
| Mouse monoclonal anti-H/K/N-Ras | BD Bioscience | Cat# 610001; RRID: AB_397424 |
| Rabbit polyclonal anti-ARAP3 | Novus | Cat# NBP1-84541; RRID: AB_11007042 |
| Mouse monoclonal anti-GAPDH | Abcam | Cat# ab8245; RRID: AB_2107448 |
| Rabbit polyclonal anti-phospho-FAK Y397 | Cell Signaling Technology | Cat# 3283; RRID: AB_2173659 |
| Mouse monoclonal anti-total FAK | BD Bioscience | Cat# 610087; RRID: AB_397494 |
| Rabbit polyclonal anti-phospho-paxillin Y31 | Abcam | Cat# ab32115; RRID: AB_777116 |
| Rabbit polyclonal anti-Arf6 (C-term.) | (Song et al., 1998) | N/A |
| Mouse monoclonal anti-Arf1 | Abcam | Cat# ab18108; RRID: AB_444251 |
| Mouse monoclonal anti-Hep70 | Invitrogen (ThermoFischer) | Cat# MA3-006; RRID: AB_325454 |
| Mouse monoclonal anti-j1-integrin | BD Bioscience | Cat# 610467; RRID: AB_2128060 |
| Rabbit polyclonal anti-Transferin receptor | Merck (Sigma-Aldrich) | Cat# HPA028598; RRID: AB_10601599 |

| **Chemicals, peptides, and recombinant proteins** |        |            |
|--------------------------------------------------|--------|------------|
| Phalloidin-AlexaFluor647 | ThermoFisher | Cat# A22287 |
| Nocodazole | Merck (Sigma-Aldrich) | Cat# M1404 |
| para-Nitroblebbistatin | Axol | Cat# ax94693 |
| PKC412 | Selleck Chemicals | Cat# S8064 |
| Cdk1/2 inhibitor III | EMD Millipore | Cat# S217714 |
| GDC-0941 | ApexBio via Stratech | Cat# A3432-APE |
| PI-103 | EMD Millipore | Cat# 528100 |
| Y-27632 | Cayman Chemical | Cat# 10005583 |
| Rapamycin | Calbiochem | Cat# 553210 |
| Mitomycin C | Merck (Sigma-Aldrich) | Cat# M4287 |

(Continued on next page)
| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| GTP·S               | Merck (Sigma-Aldrich) | Cat# G8634 |
| FuGENE HD transfection reagent | Promega | Cat# E2311 |
| FuGENE 6 transfection reagent | Promega | Cat# E2691 |
| DharmaFECT 1 Transfection Reagent | Horizon Discovery | Cat# T-2001-02 |
| JetPRIME Transfection Reagent | Polyplus | Cat# 101000046 |
| DharmaFECT Duo Transfection Reagent | Horizon Discovery | Cat# T-2010-02 |
| Cas9 nuclease mRNA | Horizon Discovery | Cat# CAS11859 |
| Edit-R tracrRNA | Horizon Discovery | Cat# U-002005-05 |
| Matrigel | Corning | Cat# 354263 |
| ProLong Gold Antifade Mountant | ThermoFisher | Cat# P10144 |
| GFP-Trap Magnetic Agarose | Chromotek | Cat# gtma-20 |
| Binding Control Magnetic Agarose Beads | Chromotek | Cat# bmab-20 |
| PAK-PBD beads | Cytoskeleton | Cat# PAK02-A |
| Sulfo-NHS-SS-Biotin | ThermoFisher | Cat# 21331 |

**Critical commercial assays**

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| Direct-zol RNA Miniprep | Zymo Research | Cat# R2051 |
| High Capacity cDNA RT kit | Applied Biosystems | Cat# 10400745 |
| QiAprep Spin Miniprep Kit | Qiagen | Cat# 27106 |
| QiAquick PCR & Gel Cleanup Kit | Qiagen | Cat# 28506 |
| QuikChange II XL Site-Directed Mutagenesis Kit | Agilent | Cat# 200523 |

**Experimental models: Cell lines**

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| HeLa                | ATCC   | Cat# CCL-2, RRID: CVCL_0030 |
| HeLa Kyoto, eGFP-knock-in for endogenous eGFP-Pi3K-C2b expression | (Wallroth et al., 2019) N/A |
| HEK293T, eGFP-knock-in for endogenous eGFP-Pi3K-C2b expression | (Marat et al., 2017) N/A |
| Mouse embryonic fibroblasts with Pi3K-C2b D1212A mutation | (Alliouachene et al., 2015) N/A |
| MDA-MB-231          | ATCC   | Cat# HTB-26; RRID: CVCL_0062 |

**Oligonucleotides**

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| DEPDIC1B ON-Targetplus SmartPool | Horizon Discovery | Cat# L-013830-00-0005 |
| RhoA ON-Targetplus SmartPool (siRNA RhoA #2) | Horizon Discovery | Cat# L-003860-00-0005 |
| Arf6 ON-Targetplus SmartPool (siRNA Arf6 #1) | Horizon Discovery | Cat# L-004008-00-0005 |
| All other siRNAs: see Table S2 | Eurofins / Sigma | N/A |
| DEPDIC1B qPCR primers: see Table S2 | Eurofins | N/A |

**Recombinant DNA**

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| Paxillin-eGFP       | Addgene | Cat# 15233 |
| pmCherry-paxillin   | Addgene | Cat# 50526 |
| pNES-IRFP-C1        | Addgene | Cat# 116863 |
| pmRFP-paxillin      | This study | N/A |
| eGFP-Pi3K-C2b WT    | (Marat et al., 2017) N/A |
| eGFP-Pi3K-C2b kinase dead | (Marat et al., 2017) N/A |
| eGFP-Pi3K-C2b WT T279A | This study | N/A |
| eGFP-Pi3K-C2b KPLP-mutant | This study | N/A |
| 6xmyc-mousePi3K-C2b | This study | N/A |
| eGFP-DEPDIC1B       | This study | N/A |
| mCherry-3x cPH-TAPP1 | Addgene | Cat# 116862 |
| GST-1Raf-RBD (1-147) | P. Rodriguez-Viciana (UCL Cancer Institute, UK) | N/A |

(Continued on next page)
RESOURCE AVAILABILITY

Lead contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, York Posor (posor@fmp-berlin.de).

Materials availability
Plasmids generated in this study will be available upon request with a complete Material Transfer Agreement or will be available through Addgene.

Data and code availability
- All original data reported in this paper will be shared by the lead contact upon request.
- This paper does not report original code.
- Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.

EXPERIMENTAL MODEL AND SUBJECT DETAILS

HeLa, MDA-MB-231 and HEK293T cells were obtained from the American Type Culture Collection (ATCC). Generation of genome-engineered HeLa Kyoto and HEK293T cells with an eGFP-coding sequence inserted following the start-codon of endogenous PI3K-C2β has been described before (Marat et al., 2017; Wallroth et al., 2019). Mouse embryonic fibroblasts from E13.5 embryos of wild-type or Pik3c2βD1212A/D1212A mice were obtained as described earlier (Alliouachene et al., 2015). Primary MEFs were immortalized by stable transduction with a p53-targeting shRNA. All cell lines were cultured in DMEM with 4.5 g/L glucose, 10% fetal bovine serum and 100 U/mL penicillin/streptomycin at 37°C and 5% CO2. All cell lines were routinely tested for mycoplasma to ensure contamination-free cultures.

METHOD DETAILS

Plasmids
Chicken Paxillin-eGFP was a gift from Rick Horwitz (Addgene #15233). Human pmCherry-paxillin was a gift from Kenneth Yamada (Addgene #50526). pmiRFP-paxillin was generated by subcloning a KpnI-Nhel fragment from MB3_pNES-iRFP-C1, a gift from Gerry Hammond (University of Pittsburgh, USA), into pmCherry-paxillin to replace mCherry with iRFP. Human eGFP-PI3K-C2β WT and kinase-dead with siRNA-resistant mutations were described earlier (Marat et al., 2017). The T279A and 1228KRDR1231 to 1228KPLP1231 mutations in eGFP-PI3K-C2β were introduced by site-directed mutagenesis using the QuikChangeII kit (Agilent) according to the manufacturer’s instructions. 6×myc-mPI3K-C2β was generated by cloning the mouse PI3K-C2β coding sequence via EcoRI/NotI into a pcDNA3.1(+) based vector with a 6×myc-tag in between the KpnI and BamHI sites. eGFP-DEPDC1B was generated by cloning a HeLa cell cDNA-amplified human DEPDC1B coding sequence via BamHI/NotI into a pcDNA3.1(+) based vector with an eGFP-tag in between the KpnI and BamHI sites. The PI(3,4)P2 sensor mCherry-3×cPH-TAPP1 was a gift from Gerry Hammond. Bacterial expression vectors for GST-hRaf-RBD (1-147) and GST-hRhotekin-RBD (7-89) were kindly provided by Pablo Rodriguez-Viciana (UCL Cancer Institute, United Kingdom). Human eGFP-ARAP3 WT (Addgene #39484), R982A (Addgene #39487) and R307A/R308A (Addgene #39486) were gifts from Sonja Vermeren. mCherry-ARAP3 was generated by inserting a PCR-amplified mCherry-tag in between the Agel and EcoRI sites in eGFP-ARAP3 WT. The siRNA-resistant constructs of eGFP-ARAP3 were
obtained through gene synthesis (Genewiz) of a NotI (nucleotide position 2797 in the ARAP3 coding sequence) to MfeI (position 6059) fragment containing a) four silent mutations in each of the four siRNA target sequences and b) destroyed EcoRI and SacII sites in the 3′-MCS. This fragment was subsequently cloned into eGFP-ARAP3 WT. The R382A (via SpeI to SacII) and R307A,R308A (via EcoRI to NotI) mutations in siRNA-resistant eGFP-ARAP3 were generated by subcloning fragments into the siRNA-resistant eGFP-ARAP3 WT construct.

**Antibodies**

Primary antibodies used in this study are listed in Table S1. Secondary HRP-coupled antibodies against mouse or rabbit IgG for WT construct.

**siRNAs**

siRNA oligonucleotides are listed in Table S2. Unless indicated otherwise, siRNA oligonucleotides were synthesized by Eurofins Genomics with 3′-dTdT overhangs and no other modifications. For DEPDC1B and ARAP3 knockdowns, pools of four siRNAs were used.

**Inhibitors and chemicals**

Small molecule inhibitors and chemicals used in this study are listed in Table S3.

**DNA and siRNA transfection**

For plasmid DNA transfection, cells were transfected with FugeneHD or Fugene6 (Promega) according to the manufacturer’s instructions. Per 6-well of HeLa cells, a total of 3.2 μg of plasmid DNA was used with 10 μL of FugeneHD or 8 μL Fugene6. Per 10 cm dish of HEK293 cells, a total of 17 μg of plasmid DNA was used with 51 μL of FugeneHD. Cells were generally analysed 24 h after transfection.

For depletion of PI3K-C2β or ARAP3, HeLa cells were transfected with siRNAs using Dharmafect 1 (Horizon Discovery) or jetPrime (Polyplus Transfection) according to the manufacturer’s instructions. Per 6-well, 0.2 nmol of siRNAs and 4 μL of Dharmafect 1 or 4 – 6 μL of jetPrime were used (this was scaled according to growth area for other culture dish sizes). Cells were analysed 72 h after siRNA transfection. In MDA-MB-231 cells, knockdowns were performed using jetPrime. Per 6-well, 0.2 nmol of siRNAs and 6 μL of jetPrime were used according to the manufacturer’s instructions.

For depletion of DEPDC1B, HeLa cells were transfected with jetPrime. Cells were seeded and simultaneously transfected (reverse transfection) on day 1, transfected again on day 2 and analysed on day 4. Per 12-well, 0.055 nmol of siRNAs and 3 μL of jetPrime were used.

Co-depletion of PI3K-C2β and RhoA or Arf6 required an extended knock-down protocol. HeLa cells were seeded on day 0, transfected using jetPrime on day 1 and day 3 and analysed 96 h after the first siRNA transfection. Per 6-well, 0.1 nmol of each siRNA and 4 μL jetPrime were used.

**Immunocytochemistry and confocal microscopy**

HeLa and MDA-MB-231 cells were seeded on glass coverslips coated with Matrigel (Corning; Matrigel HC diluted 1:50 in OptiMEM, 1 h at 37°C). Cells were fixed in 4% formaldehyde in PBS for 15 min at room temperature. To reduce cytoplasmic paxillin background, cells were instead fixed in 4% formaldehyde + 0.15% Triton X-100 in PBS for 5 min at room temperature, followed by fixation in 4% formaldehyde in PBS for another 10 min. Cells were washed three times with PBS and permeabilized in 0.2% Triton X-100 in PBS at room temperature and then blocked in 3% BSA in PBS for 1 h. Primary antibodies were diluted in 3% BSA in PBS and incubated with the cells for 2 h at room temperature or 4°C overnight. Coverslips were washed three times in PBS and incubated with secondary antibodies and phalloidin (if applicable) diluted in 3% BSA in PBS for 1 h at room temperature. Coverslips were washed and mounted on glass slides using ProLong Gold (ThermoFisher Scientific).

Laser scanning confocal microscopy was performed using Zeiss LSM700, LSM780 or LSM880 confocal microscopes. For spinning disk confocal microscopy, we used a combined spinning disk-TIRF setup (3i Intelligent Imaging Innovations, see under TIRF imaging for more details).

**TIRF imaging**

For TIRF imaging of live cells, HeLa cells were seeded on Matrigel-coated chambered coverglass 8-well slides (ThermoFisher Scientific # 155409PK or ibidi # 80827) 48 h before imaging. Before imaging, medium was changed to 300 μL per well of Fluorobrite DMEM (ThermoFisher Scientific) with 5% fetal bovine serum and 100 U/mL penicillin / streptomycin. All experiments were performed at 37°C and 5% CO2.

TIRF microscopy was performed using a combined spinning disk-TIRF setup (Zeiss - 3i Marianas SDC CSU-W1 system, 3i Intelligent Imaging Innovations) equipped with a VectorTIRF unit, Zeiss DefiniteFocus2, Prime 95B sCMOS cameras (Teledyne Photometrics), Zeiss Plan-Apochromat 63x/1.46 oil DIC M27 and Zeiss Plan-Apochromat 100x/1.46 oil DIC M27 objectives. The TIRF angle was individually adjusted for every experiment to ensure sufficiently shallow illumination depth. Per experiment, up to 50 positions across two neighbouring wells of the 8-well slide were imaged in parallel, allowing direct comparison of two treatments. For triple
colour TIRF imaging (eGFP, mCherry, iRFP) we used adjusted z-offsets for each channel and each position to compensate for chromatic aberration-induced focus differences.

**Cell extracts and immunoblotting**

 Cultured cells were washed once in cold PBS and scraped in lysis buffer (20 mM Hepes pH 7.4, 100 mM KCl, 2 mM MgCl₂, 1% Triton X-100, 1% protease and phosphatase inhibitor cocktails [Calbiochem]). After 5-15 min on ice, lysates were centrifuged at 20,800 x g at 4°C for 3 min and cleared supernatants were collected. Protein concentration was determined by Bradford assay and samples were adjusted to 1 x Laemmli sample buffer, heated to 95°C for 5 min and stored at -20°C. Samples were resolved by SDSPAGE and transferred to nitrocellulose membranes using wet blotting (Bio-Rad) or dry blotting (iBlot2, ThermoFisher Scientific). Primary antibodies (see Table S1) were diluted in 3% BSA, 0.02% NaN₃ in TBS and incubated on the blots shaking at 4°C overnight or for two days. Secondary HRP-conjugated antibodies were diluted in 3% milk powder in TBS and incubated on the blots for 1-2 h at room temperature. Chemiluminescence was detected with a LAS4000 digital imaging system (GE Healthcare).

**Immunoprecipitations**

For immunoprecipitation from transiently eGFP-DEPDC1B and 6xmyc-PI3K-C2β expressing HEK293T cells, cells on 10 cm dishes were harvested 48 h after transfection. Cells were centrifuged at 20,800 x g at 4°C for 10 min, cleared lysates were collected and protein concentration was determined by Bradford assay. Cleared lysates were incubated with 5 μg of primary antibodies, i) anti-c-Myc or anti-Flag as a control, ii) anti-DEPDC1B (Biortbyt) or anti-mouse IgG as a control bound to magnetic protein A or G beads rotating at 4°C overnight. Beads were washed five times in lysis buffer and bound proteins were eluted using 1 x Laemmli sample buffer.

For immunoprecipitation from genome-engineered HEK293T cells with endogenous eGFP-PI3K-C2β, cells were seeded onto 10 cm dishes coated with poly-L-lysine (Sigma-Aldrich). Cells were washed once in ice-cold PBS and collected in IP buffer (20 mM Hepes pH 7.4, 150 mM NaCl, 0.05% saponin, 1% protease and phosphatase inhibitor cocktails [Calbiochem]). Crude lysates were centrifuged at 20,800 x g at 4°C for 10 min, cleared lysates were collected and protein concentration was determined by Bradford assay. Cleared lysates were incubated with control or GFP-trap magnetic beads (ChromoTek) for 4 h rotating at 4°C. Beads were washed five times in IP buffer and bound proteins were eluted using 1 x Laemmli sample buffer.

**GTPase pull-down assays**

GST-hRaf-RBD (1-147), GST-hRhotekin-RBD (7-89) and GST-hGGA3-VHS-GAT (1-313) were expressed in E. coli and purified by batch method on GSH-agarose (ThermoFisher Scientific). Per pull-down, we used 80 μg of fusion protein. GST-Pak-PBD beads were obtained from Cytoskeleton; per pull-down, 50 μg of fusion protein were used. As a positive control, we used GTPγS-loaded HeLa extract (see below) prepared by sequentially adjusting the cleared lysate to 15 mM EDTA, adding to 0.2 mM GTPγS (Sigma-Aldrich) and incubating at 30°C for 15 min, transferring to ice and adjusting to 60 mM MgCl₂.

SiRNA-treated HeLa cells (one 15 cm dish per pull-down sample) were washed once with ice-cold PBS and collected in GTPase lysis buffer (G-LB: 50 mM Tris pH 7.2, 500 mM NaCl, 10 mM MgCl₂, 1% Triton X-100, 1% phosphatase inhibitor cocktail [Calbiochem] + one tablet complete mini protease inhibitor, EDTA-free [Merck] per 7 mL). Crude lysates were immediately centrifuged at 20,800 x g at 4°C for 2 min and cleared lysates incubated with GST-hRaf-RBD, GST-hRhotekin-RBD or GST-Pak-PBD beads rotating at 4°C for 1 h. Unbound supernatant was discarded, beads were sucked dry using a needle and washed once in 25 mM Tris pH 7.2, 150 mM NaCl, 10 mM MgCl₂, 1% Triton X-100. Bound proteins were eluted using 1 x Laemmli sample buffer.

**Scratch wound migration assay**

siRNA-treated HeLa cells were seeded to Matrigel-coated 6-wells and grown to a confluent monolayer. A scratch wound was introduced using a P200 pipette tip followed by washing cells twice with PBS and addition of fresh culture medium with 10% FBS containing 1 μg/mL mitomycin C (to block cell proliferation and thereby to assess migration independently of proliferation). Wound closure was documented at 0 h, 8 h and 24 h using an EVOS DIC microscope (ThermoFisher Scientific) and percentage closure of the initial wound was quantified using ImageJ.

For scratch wound assays with immortalized MEFs, cells were seeded in non-coated 6-wells and grown to confluence. For PDGF-stimulated wound closure, cells were starved of serum overnight. A scratch wound was made as described above and cells were allowed to migrate in DMEM + 50 ng/mL PDGF (no serum) or in full medium with 10% FBS. Proliferation was inhibited using 10 μg/mL mitomycin C.

**Nocodazole washout assay**

siRNA-treated HeLa cells seeded on Matrigel-coated glass coverslips were treated with 10 μM nocodazole for 2 h to depolymerize microtubules and inhibit adhesion disassembly. Synchronously adhesion disassembly was triggered by removal of nocodazole with two washes in PBS, and cells were incubated in full medium for 15 min to allow adhesion disassembly to proceed. Cells were fixed using 4% formaldehyde for 15-20 min and stained for paxillin and α-tubulin.

For nocodazole washout in MEFs, cells on uncoated glass coverslips were serum-starved overnight and treated with 10 μM nocodazole for 2 h. After 10 minutes of nocodazole washout, cells were fixed and stained for paxillin or α-tubulin.
Yeast-2-hybrid screen
A genome-wide ULTimate yeast-2-hybrid screen was performed by Hybrigenics Services (Paris, France) with a bait construct encoding amino acids 1-615 of human PI3K-C2b cloned in pB29 (N-bait-LexA-C fusion) against a human placenta_RPS5 complementary cDNA Gal4-activating domain-fusion library.

RNA isolation and RT-qPCR
HeLa cells were grown in 6-wells and RNA extracted using the Direct-zol RNA MiniPrep kit (Zymo) according to the manufacturer’s instructions. cDNA was generated by reverse transcription of 200 - 250 ng of purified RNA using the High Capacity cDNA RT kit (Applied Biosystems). Quantitative PCR reactions were run using the PowerUP SYBR Green Master Mix (Applied Biosystems) on a QuantStudio6 Real-Time PCR System (Applied Biosystems). Mean Ct values were calculated from technical replicates and gene expression was calculated using a standard curve from serially diluted pooled input material. Target gene expression was then normalized to β-actin expression and expression in siScrambled-treated cells was set to 1. Sequences of qPCR primers are listed in Table S2.

Genome-editing using CRISPR/Cas9
HeLa cells were transfected with fluorescently labelled mKate2-Cas9 mRNA (Horizon), tracrRNA (Horizon) and crRNA (5’-TTTGGTCTGCGGTCACCTCA, Horizon) using Dharmafect DUO (Horizon) according to the manufacturer’s instructions. The following day, single mKate2-positive cells were sorted into 96-wells using fluorescence-activated cell sorting and single-cell clones were expanded. For screening of clones, genomic DNA was extracted using DirectPCR Lysis Reagent (Viagen Biotech) containing 1 mg/mL proteinase K (Sigma-Aldrich) and the targeted genomic region was amplified by PCR (fwd: 5’- CCATTGCCACCATCATTCTGC, rev.: 5’-GGAAGGTCAACAGACCTTGACC) followed by Sanger-sequencing. Sequencing results were analysed using the ICE analysis tool v2 (Synthego, https://ice.synthego.com/) to infer the identity and contribution of individual alleles in each clone.

Generation of mouse embryonic fibroblasts
Primary mouse embryonic fibroblasts (MEFs) were obtained from E13.5 embryos from timed pregnancies with the day of the copulation plug counted as E0.5. Decapitated embryos were minced and cells dissociated using trypsin. Single cell suspensions were allowed to adhere to culture dishes in DMEM with 4.5 g/L glucose, 10% fetal bovine serum and 100 U/mL penicillin/streptomycin at 37°C and 5% CO2. Early passage primary MEFs (P2 to P5) were immortalized by retroviral transduction with a p53-shRNA construct and selected with 2 μg/mL puromycin for 10-14 days.

Surface biotinylation β1-integrin endocytosis
SiRNA-treated HeLa cells were starved in serum-free medium for 45 min, transferred to ice and washed twice with PBS. Surface-exposed proteins were biotinylated using 0.5 mg/mL Sulfo-NHS-SS-Biotin (ThermoFisher Scientific) in PBS at 4°C. Cells were washed twice with 50 mM glycine in TBS to stop the biotinylation reaction. For integrin internalization, cells were incubated with pre-warmed full medium for 10 – 30 min at 37°C. Surface-exposed biotin was cleaved using 50 mM TCEP (Carl Roth) in TBS. Cells were lysed in Biotin-LB (75 mM Tris-HCl pH 7.5, 200 mM NaCl, 7.5 mM EDTA, 7.5 mM EGTA, 1.5% Triton X-100, 0.75% Igepal CA-630). Biotinylated proteins were purified using magnetic streptavidin beads (Pierce, ThermoFisher Scientific). Lysates and purified biotinylated proteins were analysed by immunoblotting using detection by fluorescent antibody-conjugates (LI-COR Biosciences).

Measurement of mitotic rounding
siRNA-treated HeLa cells were seeded to matrigel-coated (Sigma-Aldrich), glass-bottomed plates (Mattek) 24 hours before imaging. Wide field, brightfield time-lapse imaging at 37°C was carried out on a Nikon Ti inverted microscope at 5 minute intervals using a 20x (Plan Fluor ELWD Ph1 NA 0.45, WD 7.4) objective. Images were processed and analysed using ImageJ (Schindelin et al., 2012). For cell rounding rate analysis, cells were aligned so that time-point 0 represents nuclear envelope breakdown (NEB). Cell outlines for 20 cells in each condition were manually segmented from consecutive bright-field images from 30 minutes before NEB until the end of metaphase (defined as the frame before anaphase) using the polygon selections tool in ImageJ. Cell area was measured at every time-point and rounding rate was calculated as the difference in cell area between consecutive time-points divided by the time difference.

QUANTIFICATION AND STATISTICAL ANALYSIS
Image analysis
All image analysis was performed using ImageJ (Schindelin et al., 2012). For analysis of live imaging data, time lapse series were corrected for x-y-shifts in between frames using the ImageJ plug-in “Correct 3D drift” (Parslow et al., 2014). For analysis of paxillin-labelled adhesion lifetimes, we used the plug-in “TrackMate” (Tinevez et al., 2017), with following parameters: estimated blob diameter 2 μm; threshold 0.3; individual filtering by quality to match bona fide adhesions; LAP tracker: max. frame to frame distance 2 μm, gap max. distance 2 μm, max. frame gap 1.5 μm, splitting and merging up to 1.5 μm; excluded tracks with a lifetime of less than 30 min. For experiments with addition of para-Nitroblebbistatin, background subtraction was used in the 488 channel from a ROIs drawn outside of the cell to compensate for the increase in background fluorescence caused by the fluorescent properties of...
para-Nitroblebbistatin. For quantification of protein recruitment to adhesions as labelled by paxillin, we identified the ratio of mean intensity at adhesions over the mean intensity in the rest of the cell as the most robust read-out. This allows for unbiased quantification without the need of subjective intensity thresholding and eliminates increases in fluorescence in the cell caused by blebbistatin addition that had not been removed by background subtraction.

Statistics
Statistical analyses were performed with Graphpad Prism 9 software and details of all statistical analyses are provided in the respective figure legends. For all tests, the levels of statistical significance were defined as: *$P < 0.05$, **$P < 0.01$, ***$P < 0.001$ and ****$P < 0.0001$. When two experimental conditions or groups were being compared, we used an unpaired two-tailed t-test with Welch’s correction to compensate for the possibility of unequal variances in the two conditions. For comparisons between more than two experimental conditions, we used analysis of variance (ANOVA) followed by Tukey’s test (for comparisons between all conditions and groups) or Šidák’s test (for multiple pairwise comparisons) to compute $P$ values. $P$ values from ANOVAs are reported as multiplicity-adjusted $P$ values.
Local synthesis of the phosphatidylinositol-3,4-bisphosphate lipid drives focal adhesion turnover

York Posor, Charis Kampyli, Benoit Bilanges, Sushila Ganguli, Philipp A. Koch, Alexander Wallroth, Daniele Morelli, Michalina Jenkins, Samira Alliouachene, Elitza Deltcheva, Buzz Baum, Volker Haucke, and Bart Vanhaesebroeck
Figure S1: Accumulation of focal adhesions and impaired migration in fibroblasts from mice with kinase-inactive PI3K-C2β, and HeLa or MDA-MB-231 cells depleted of PI3K-C2β.

(A-D) Mouse embryonic fibroblasts (MEFs) were obtained from Pik3c2b

wt/wt or Pik3c2bD1212A/D1212A mice and immortalized by stable p53-knockdown. The D1212A mutation abolishes kinase activity.

(A, B) Accumulation of focal adhesions in MEFs from PI3K-C2β-kinase-inactive mice. MEFs were stained for paxillin and imaged by confocal laser scanning microscopy. (A) Bar, 20 µm. (B) Mean + s.d. from n = 3 independent experiments; unpaired two-tailed t-test with Welch’s correction.

(C, D) Impaired migration in MEFs from PI3K-C2β-kinase-inactive mice in a scratch wound assay in presence of only PDGF but no serum (C and D) or complete medium with 10 % serum (D). Wound closure was assessed after 8 h and 24 h. (C) Bar, 200 µm. (D) Mean + s.d. from n = 4 independent experiments, two-way ANOVA with Sidak’s test.

(E, F, G) Accumulation of focal adhesions, F-actin and impaired migration in HeLa cells depleted of PI3K-C2β using an alternative siRNA, siRNA #2. HeLa cells were depleted of PI3K-C2β by siRNA transfection. (E) Immunoblots of cell extracts representative of at least 3 independent experiments. Tubulin was detected as loading control. (F) Cells were stained for paxillin and for F-actin using phalloidin, followed by imaging by spinning disk confocal microscopy. Mean + s.d. from n = 3 independent experiments, unpaired two-tailed t-test with Welch’s correction. (G) Scratch wound assay, with wound closure assessed after 8 h and after 24 h in complete medium containing serum and mitomycin C to block proliferation. Mean + s.d. from n = 3 independent experiments, unpaired two-tailed t-test with Welch’s correction.

(H, I, J) Accumulation of focal adhesions and F-actin in cells of the migratory breast cancer line MDA-MB-231 depleted of PI3K-C2β by siRNA transfection. (H) Immunoblots of cell extracts representative of 3 independent experiments. Tubulin was detected as loading control. (I, J) Cells were stained for paxillin and for F-actin using phalloidin, followed by imaging by spinning disk confocal microscopy. (I) Bar, 20 µm. (J) Mean + s.d. from n = 3 independent experiments, unpaired two-tailed t-test with Welch’s correction.

Related to Fig. 1. FAs, focal adhesions.
Figure S2

A

siScrambled

siPI3K-C2β

B

siScrambled  siPI3K-C2β

FAs per cell

C

siScrambled  siPI3K-C2β

Cell area

D

WT

2 h nocodazole + 10 min washout

E

WT

PI3K-C2βD1212A/D1212A

% adhesions remaining

F

siScrambled  siPI3K-C2β

Cell area (µm²)

time from NEB [min]
Figure S2: Perturbation of PI3K-C2β impairs focal adhesion disassembly but not de novo adhesion formation.

(A - C) HeLa cells depleted of PI3K-C2β were trypsinized to cleave surface adhesion molecules and re-seeded on Matrigel-coated coverslips. Cells were allowed to adhere and spread for 0.5 to 6 h before staining for paxillin and imaging by laser scanning confocal microscopy (A) Bar, 20 µm. (B) The number of focal adhesions in PI3K-C2β-depleted cells only starts to diverge from control cells at 4 h after plating. Mean ± s.d. from n = 3 independent experiments, two-way ANOVA with Sidak’s test. (C) Cell area in PI3K-C2β-depleted cells only begins to differ from control cells at 4-6 h after plating. Mean ± s.d. from n = 3 independent experiments, two-way ANOVA with Sidak’s test.

(D, E) Cell-matrix adhesion disassembly is impaired in MEFs from PI3K-C2β-kinase-inactive mice. Adhesion disassembly was stalled for 2 h by nocodazole treatment. Synchronous adhesion disassembly was then triggered by nocodazole washout. After 10 min, cells were fixed, stained for paxillin and imaged by laser scanning confocal microscopy. (D) Bar 20 µm. (E) Adhesions remaining 10 min after nocodazole washout (in percent of adhesions at 2 h nocodazole treatment). Mean ± s.d. from MEF cell lines obtained from n = 3 mouse embryos for WT and PI3K-C2βD1212A/D1212A each, with data for each cell line obtained by averaging over two to three independent experiments; unpaired two-tailed t-test with Welch’s correction.

(F) The rate of cell area change during mitotic rounding is not significantly affected in HeLa cells depleted of PI3K-C2β. HeLa cells were imaged by phase-contrast time-lapse microscopy and the cell area was measured at time points before and after nuclear envelope breakdown (NEB). Mean ± or – s.d. from n = 20 cells per condition.

Related to Fig. 2. FAs, focal adhesions.
Figure S3: Identification of DEPDC1B as an interaction partner of PI3K-C2β.

(A) Scheme depicting a yeast-2-hybrid screen using the N-terminal 615 amino acids of PI3K-C2β as a bait. This screen identified DEPDC1B, a protein previously implicated in focal adhesion disassembly, as an interaction partner of PI3K-C2β. The fragment of DEPDC1B that interacted with the bait encompasses amino acids 114 – 260 of human DEPDC1B.

(B) Validation of DEPDC1B as an interaction partner of PI3K-C2β. HEK293 cells transiently expressing 6×myc-PI3K-C2β, eGFP-DEPDC1B or both were subjected to immunoprecipitation of myc or eGFP. Immunoprecipitation of either 6×myc-PI3K-C2β or eGFP-DEPDC1B co-precipitated the other protein, but not β-actin. For the right panel, irrelevant lanes in between input and IPs have been spliced out but all lanes originate from the same blot. Data shown are representative of at least 5 (from 6×myc-PI3K-C2β side) or 2 (from eGFP-DEPDC1B side) independent experiments.

Related to Fig. 4.
Figure S4

A

control

DEPDC1B KO clone 1

DEPDC1B KO clone 2

contribution

DEPDC1B KO clone 1

56 % C T G A C C C T T G G T G G T C A C T

28 % C T G A C C C T T G G T G G T C A C T

9 % C T G A C C C T T G G T G G T C A C T

DEPDC1B KO clone 2

59 % C T G A C C C T T G G T G G T C A C T

24 % C T G A C C C T T G G T G G T C A C T

6 % C T G A C C C T T G G T G G T C A C T

2 % C T G A C C C T T G G T G G T C A C T

B

| eCFP | eCFP-DEPDC1B |
|------|-------------|
| WT clone | DEPDC1B KO clone 2 |

C

WT

DEPDC1B KO 1

DEPDC1B KO 2

F-As per cell

F-actin per cell

eGFP
eGFP-DEPDC1B

* p < 0.05

** p < 0.01

*** p < 0.001

**** p < 0.0001
Figure S4: Knockout of DEPDC1B in HeLa cells phenocopies depletion of PI3K-C2β.

(A) HeLa cells were genome-targeted to generate DEPDC1B knockout (KO) cells using CRISPR/Cas9. Single cell clones were expanded and subjected to Sanger sequencing, followed by analysis of the contribution of individual alleles using the ICE tool (https://ice.synthego.com/#/). The upper panel shows sequencing traces for two clones DEPDC1B KO 1 and KO 2 in comparison to a non-edited sample. The sequence of the crRNA (the targeting sequence within the guide RNA) used is underlined and the designated cut site is indicated with a dashed line. The lower panel shows the inferred contribution of individual alleles. Both clones showed >90% predicted KO efficiency.

(B, C) KO of DEPDC1B phenocopies depletion of PI3K-C2β. HeLa clones either WT or KO for DEPDC1B were transiently transfected with eGFP or eGFP-DEPDC1B. Cells were stained for paxillin and for F-actin using phalloidin and imaged by spinning disk confocal microscopy. (B) Bar 20 µm. (C) Mean ± s.d. from n = 3 independent experiments, two-way ANOVA with Sidak’s test.

Related to Fig. 4. FAs, focal adhesions.
Figure S5: A mutant PI3K-C2β which can only produce PtdIns(3)P does not rescue accumulation of focal adhesions in PI3K-C2β-depleted cells.

(A, B) Mutation of residues 1228KRDR1231 to 1228KPLP1231 in the substrate-binding activation loop renders PI3K-C2β incapable of producing PtdIns(3,4)P₂, whereas synthesis of PtdIns(3)P remains unperturbed. HeLa cells depleted of PI3K-C2β using siRNAs were transfected with eGFP or either siRNA-resistant WT or KPLP-mutant eGFP-PI3K-C2β and stained for paxillin. Images were acquired using a spinning disk confocal microscope. (A) Bar 20 µm. (B) Mean ± s.d. from n = 4 independent experiments, 2-way ANOVA with Tukey's test.

Related to Fig. 5.
Figure S6: ROCK inhibition rescues increased phospho-MLC2S19 levels in PI3K-C2β-depleted cells.

(A, B) HeLa cells depleted of PI3K-C2β using siRNAs were treated for 16 h (overnight) with the ROCK inhibitor Y-27632 and cell lysates analysed by immunoblotting for the indicated proteins. A low dose of Y-

Figure S6: ROCK inhibition rescues increased phospho-MLC2S19 levels in PI3K-C2β-depleted cells.

(A, B) HeLa cells depleted of PI3K-C2β using siRNAs were treated for 16 h (overnight) with the ROCK inhibitor Y-27632 and cell lysates analysed by immunoblotting for the indicated proteins. A low dose of Y-

...
27632 (1 µM) reduces phospho-MLC2\textsuperscript{S19} in PI3K-C2β-depleted cells to control levels. (A) Data shown are representative of four independent experiments. (B) Densitometric analysis of immunoblots as shown in (A). Mean + s.d. from n = 4 (MLC2 pS19, paxillin pY31) or n = 3 (FAK pY397) independent experiments, two-way ANOVA with Tukey’s test.

(C) Co-depletion of PI3K-C2β with RhoA or Arf6 using siRNAs. Representative blots from two independent experiments are shown. Vinculin, Hsp70 and α-tubulin were detected as loading controls.

Related to Fig. 6.
Figure S7: Total β1-integrin endocytosis is unaffected and Rapamycin does not rescue accumulation of focal adhesions in cells depleted of PI3K-C2β.

(A) HeLa cells were depleted of PI3K-C2β using siRNAs and the amount of β1-integrin internalized after different time points was measured using a surface-biotinylation and streptavidin-pull-down assay (see STAR methods). In brief, after incubation at 37°C for the indicated time (uptake), surface-exposed biotin was cleaved using TCEP and biotinylated proteins were purified using magnetic streptavidin beads. Levels of proteins in lysates or purified samples were analysed using fluorescent detection of immunoblots. The blots shown are representative of four independent experiments.
(B, C) HeLa cells depleted of PI3K-C2β were treated overnight with vehicle or 100 nM rapamycin, stained for paxillin and imaged by confocal microscopy. (A) bar 20 µm. (B) Mean ± s.d., ordinary one-way ANOVA with Tukey's test. FAs, focal adhesions.

Related to Fig. 6 and 7.
## Supplementary table 1

**Supplementary table 1: Antibodies used in this study. Related to STAR Methods.**

| antigen                   | host species | IF dilution | blotting dilution | manufacturer                  | order number |
|---------------------------|--------------|-------------|-------------------|-------------------------------|--------------|
| Paxillin                  | mouse        | 1:400       | 1:4000            | BD Bioscience                 | 610051       |
| phospho-MLC2 S19          | mouse        | 1:100       | 1:1000            | Cell Signaling Technology     | 3675         |
| total MLC2                | rabbit       |             | 1:1000            | Cell Signaling Technology     | 3672         |
| α-tubulin (clone B-5-1-2) | rabbit       | 1:400       | 1:4000            | Sigma                         | T5168        |
| c-myc (clone 9E10)       | mouse        | 1:1000      |                   | Abcam                         | ab32         |
| FLAG                      | mouse        |             |                   | Merck (Sigma-Aldrich)         | F-3165       |
| Mouse IgG                 | rabbit       |             |                   | Merck (Sigma-Aldrich)         | M-7023       |
| DEPDC1B                   | rabbit       |             |                   | Biorbyt                       | orb183064    |
| DEPDC1B (clone 2H2)      | mouse        | 1:500       |                   | My Biosource                  | mbs154376    |
| β-actin (clone AC15)     | mouse        | 1:10,000    |                   | Merck (Sigma-Aldrich)         | A1978        |
| PI3K-C2β                  | mouse        | 1:250       |                   | BD Bioscience                 | 611342       |
| Talin                     | mouse        | 1:500       |                   | Merck (Sigma-Aldrich)         | T3287        |
| eGFP                      | rabbit       | 1:800       | 1:20,000          | Abcam                         | ab6556       |
| Erk1/2                    | rabbit       | 1:1,000     |                   | Cell Signaling Technology     | 9102         |
| pan 14-3-3                | mouse        | 1:500       |                   | Santa Cruz Biotechnology      | sc-1657      |
| RhoA                      | rabbit       | 1:250       |                   | Cell Signaling Technology     | 2117         |
| Rac1 (clone 23A8)        | mouse        | 1:1,000     |                   | Merck                         | 05-389       |
| Cdc42                     | rabbit       | 1:500       |                   | Cell Signaling Technology     | 2462         |
| vinculin                  | rabbit       | 1:10,000    |                   | Merck (Sigma-Aldrich)         | V9131        |
| R-Ras                     | rabbit       | 1:250       |                   | Cell Signaling Technology     | 8446         |
| H/K/N-Ras                 | mouse        | 1:250       |                   | BD Bioscience                 | 610001       |
| ARAP3                     | rabbit       | 1:500       |                   | Novus                         | NBPI-84541   |
| GAPDH                     | mouse        | 1:10,000    |                   | Abcam                         | ab8245       |
| phospho-FAK Y397          | rabbit       | 1:500       |                   | Cell Signaling Technology     | 3283         |
| total FAK                 | mouse        | 1:500       |                   | BD Bioscience                 | 610087       |
| phospho-paxillin Y31     | rabbit       | 1:3,000     |                   | Abcam                         | ab32115      |
| Arf6 (C-term.)           | rabbit       | 1:200       |                   | Gift from J. Donaldson Song et al., J Cell Sci (1998) 111 (15): 2257–2267. | -           |
| Arf1                      | mouse        | 1:500       |                   | Abcam                         | ab18108      |
| Hsp70                     | mouse        | 1:5,000     |                   | Invitrogen (ThermoFischer)    | MA3-006      |
| β1-integrin               | mouse        | 1:400       |                   | BD Bioscience                 | 610467       |
| Transferrin receptor      | rabbit       | 1:1,000     |                   | Merck (Sigma-Aldrich)         | HPA028598    |
Supplementary table 2

Supplementary table 2: siRNAs and qPCR primers used. Related to STAR Methods.

| siRNA sequences | target (all human) | number if pool-of-four | sequence (5'-3') | reference | manufacturer |
|-----------------|-------------------|------------------------|------------------|-----------|--------------|
| non-targeting (siScrambled) | | | AUUGUUAACCGUAUUCUUA | Marat et al. Science 356, 2017 ("siRNA #2") | Eurofins |
| PI3K-C2β #1 | | | GCUACCAGCUAUGAAGAUU | Marat et al. Science 356, 2017 ("siRNA #2") | Eurofins |
| PI3K-C2β #2 | | | GUUCGACACUUAACCACAAU | Marat et al. Science 356, 2017 ("siRNA #1") | Eurofins |
| DEPDC1B | #1 | | GUACACAAGCGUCACAGUAUU | | Horizon Discovery # L-013830-00-0005 |
| | #2 | | CGAAGUUCAUCAUCCAUA | | Eurofins |
| | #3 | | GUACUGGCUUUGUUACAGA | | Eurofins |
| | #4 | | GCGUGUGGCUCACUUACGA | | Eurofins |
| ARAP3 | #1 | | GUAAUGAGAUAUGACAGU | Gambardella et al., Sci Signal 3, 2010 | Eurofins |
| | #2 | | GCAGAAAUUGUGCGGCUCAU | | Eurofins |
| | #3 | | ACACGGGAUGUGGACAGUGA | | Eurofins |
| | #4 | | GAACGGGAGUGCCUUGG | | Eurofins |
| RhoA #1 | | | GAUCACGAUGUUUAUACGAUGUGU | Marchesi et al., Dev Cell 31, 2014 | Sigma-Aldrich |
| RhoA #2 | #1 | | CGACACGCCCUGUAUGUUA | | Horizon Discovery # L-003860-00-0005 |
| | #2 | | GACCAAGAUGUGAGUGA | | Eurofins |
| | #3 | | GCAGAGAUAUGGCAAACAG | | Eurofins |
| | #4 | | GGAUGAGAUGACACAAAAG | | Eurofins |
| Arf6 #1 | #1 | | CGGCAUUACUACUGGG | Horizon Discovery # L-004008-00-0005 | Eurofins |
| | #2 | | UCACAUGUUAACCUCUAA | | Eurofins |
| | #3 | | GAGCUGCACCUGCAUUAUCA | | Eurofins |
| | #4 | | GAUGAGGGACGCCUAUAUC | | Eurofins |
| Arf6 #2 | | | AACCAUUAUACAGGAUUAU | Moravec et al., J Biol Chem 287, 2012 ("Arf6–1") | Eurofins |

| qPCR primers | target gene / primer | amplificate length | sequence (5'-3') |
|--------------|----------------------|--------------------|------------------|
| DEPDC1B fw | 182 bp | GAGCTACCAGGCTGTGAATG |
| DEDC1B rev | 182 bp | CGTTGTGTCGGCTACTT |
### Supplementary table 3

**Supplementary table 3: Inhibitors and small molecules used in this study. Related to STAR Methods.**

| Compound                        | concentration used | Supplier                  | order number |
|---------------------------------|--------------------|---------------------------|--------------|
| Phalloidin-AlexaFluor647        | 1:500              | ThermoFisher Scientific   | A22287       |
| Nocodazole                      | 10 µM              | Merck (Sigma-Aldrich)     | M1404        |
| para-Nitroblebbistatin          | 25 µM              | Axol                      | ax494693     |
| PKC412                          | 1 µM               | Selleck Chemicals         | S8064        |
| Cdk1/2 inhibitor III            | 2 µM               | EMD Millipore             | S217714      |
| GDC-0941                        | 250 nM             | ApexBio via Stratech      | A3432-APE    |
| PI-103                          | 1 µM               | EMD Millipore             | 528100       |
| Y-27632                         | 1 µM               | Cayman Chemical           | 10005583     |
| Rapamycin                       | 100 nM             | Calbiochem                | 553210       |
| Mitomycin C                     | 1 µg/mL (HeLa), 10 µg/mL (MEFs) | Merck (Sigma-Aldrich) | M4287        |
| GTPγS                           | 0.2 mM             | Merck (Sigma-Aldrich)     | G8634        |